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Abstract   
RNA-based therapeutics have emerged as one of the most powerful therapeutic options 
used for the modulation of gene/protein expression and gene editing with the potential to 
treat neurodegenerative diseases. However, the delivery of nucleic acids to the central 
nervous system (CNS), in particular by the systemic route, remains a major hurdle. This 
review will focus on the strategies for systemic delivery of therapeutic nucleic acids 
designed to overcome these barriers. Pathways and mechanisms of transport across the 
blood-brain barrier which could be exploited for delivery are described, focusing in 
particular on smaller nucleic acids including antisense oligonucleotides (ASOs) and small 
interfering RNA (siRNA). Approaches used to enhance delivery including chemical 
modifications, nanocarrier systems, and target selection (cell-specific delivery) are 
critically analysed. Learnings achieved from a comparison of the successes and failures 
reported for CNS delivery of ASO versus siRNA will help identify opportunities for a 
wider range of nucleic acids and accelerate the clinical translation of these innovative 
therapies. 
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1. INTRODUCTION  
Neurological disorders are the leading cause of disability and the second leading 
cause of death worldwide 1. The incidence of neurological disorders is increasing in 
tandem with the aging of the population, representing a serious economic burden to 
society. Therefore, research is urgently needed to develop novel treatments in response 
to this clinical need 2.  
Gene therapy has emerged as a powerful therapeutic approach for the treatment 
of neurological diseases. Three different approaches can be used: (i) overexpression of 
genes, (ii) silencing of the disease-causing gene by RNA interference (RNAi), and (iii) 
gene editing by the insertion, removal or replacement of genes in the genome using zinc 
finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and 
the recently developed clustered regularly interspaced short palindromic repeats 
(CRISPR)/associated protein 9 (Cas9) tools 3,4. 
For decades, overexpression of a missing gene product by an exogenous DNA 
sequence was the only approach for gene therapy. This approach typically utilizes viral 
vectors as delivery systems, which have been associated with insertional mutagenesis, 
innate and adaptive immune responses and toxic effects 5. Since the development of RNAi 
almost two decades ago, this technology has been intensively exploited and many clinical 
trials have been performed 6,7. Antisense oligonucleotides (ASOs) and small interfering 
RNA (siRNA) are the two most widely studied approaches for silencing gene expression, 
particularly with respect to the CNS. The main advantages associated with RNA 
therapeutics are the high specificity to target pathogenic targets, decreasing toxicity 
associated with off-target effects, and relatively low dose requirement for therapeutic 
effect 8–10.  In comparison to RNAi, gene-editing tools exhibit more complex 
physicochemical and biopharmaceutical properties and are consequently more 
challenging to deliver especially to the brain 11. Thus, this review will focus solely on the 
gene silencing approach. 
Therapeutic targeting of RNA is currently based on two main approaches: single-
stranded ASOs and double-stranded RNAi. RNAi process can be mediated by siRNAs, 
endogenous microRNAs (miRNA), and short hairpin RNA (shRNA). In contrast to 
siRNA that acts in the cytosol, miRNA and shRNA require transport into the nucleus, an 
additional barrier to RNAi delivery 12. Regarding drug development, siRNA is more 
suitable for drug use because it does not require genome integration and can be easily 




ASOs are synthetic single-stranded nucleic acids generally containing 12–30 
nucleotides in length (4-10 kDa), designed to bind a target RNA (pre-mRNA, mRNA, 
non-coding RNA) in a sequence-specific manner via Watson-Crick base-pairing rules. 
The single-stranded nature of ASOs may result in lower costs and simplify the delivery 
process when compared to siRNAs 14. ASOs regulate RNA modulation either by mRNA 
cleavage through enzymatic degradation (RNase H) or by an occupancy-only mechanism, 
sometimes referred to as steric blocking. Furthermore, they can also modulate pre-mRNA 
splicing, reducing or restoring protein expression 15–17. 
RNase H triggering represents the most predominant knockdown mechanism. As 
illustrated in Figure 1, upon the introduction into cells, ASOs can enter the nucleus and 
engage with complementary sequences in pre‐mRNAs. The formation of a DNA/RNA 
hybrid results in the recruitment of RNase H1, a ribonuclease that recognizes the 
DNA/RNA heteroduplex and catalyses the cleavage of RNA, resulting in reduced mRNA 
levels 18,19. 
 siRNAs are short double-stranded RNA molecules usually containing 19–25 base 
pairs (~14 kDa) that regulate gene expression and control a diverse array of biological 
processes. They consist of two strands: (i) the guide strand (antisense), containing the 
information for target-gene recognition, and (ii) the passenger strand (sense) required for 
loading into the RISC (RNA-induced silencing complex). Once in the cytoplasm, the 
RNAi process starts with the cleavage of long double-stranded RNA into siRNA by the 
Dicer enzyme (initiation phase). As shown in Figure 1, these small RNAs are then 
incorporated into the RISC (effector phase). The RISC nuclease Argonaute 2 (Ago2), 
cleaves siRNA strands and releases the guide strand, resulting in RISC activation. The 
guide strand anneals with its complementary mRNA leading to its degradation and the 
silencing of the targeted gene. The activated RISC complex (with antisense strand 
included) can move on, to degrade additional targeted mRNA, allowing transient (3–
7 days) gene silencing in rapidly dividing cells and, extending for several weeks, in slowly 






Figure 1.  RNAi-based therapeutic main approaches: single-stranded antisense 
oligonucleotides (ASOs) and double-stranded small interfering RNA (siRNA).  ASOs: Once 
bound to the target mRNA, ASOs can form an RNA–DNA hybrid that becomes a substrate for 
RNase H, which results in mRNA degradation. siRNA: double-stranded RNA (dsRNA) is 
processed by Dicer into siRNA. The guide RNA strand is incorporated into the RNA-induced 
silencing complex (RISC) and Argonaute 2 (Ago2). Ago2 cleaves the passenger strand and 
siRNA/RISC complex then binds the complementary sequence of the target mRNA resulting in the 
degradation of the target transcript.  
 
Although there has been a great progress, the treatment of neurological disorders 
using nucleic acids remains a challenging issue due to rapid degradation in the circulation, 
poor cellular uptake, lack of specificity for particular brain cell/tissues, and the complex 
structure of the brain and physiological barriers, especially the blood-brain-barrier (BBB) 
8, which restricts access to the central nervous system (CNS) 22,23.  
The BBB is one of the most selective physiological barriers, regulating the 
transport of molecules, ions, and cells into and out of the brain and protecting the CNS 
from potentially harmful substances that enter the bloodstream. At the same time, the 
BBB controls CNS nutrition and homeostasis and maintains the chemical composition of 
the neuronal milieu required for proper neuronal functioning. The BBB is formed by a 




junctions (AJ), which together with astrocytes, pericytes, neurons, and the basement 
membrane constitute the neurovascular unit 23–25.  The complexity of the BBB restricts 
CNS drug delivery, thus limiting the treatment of several neurological diseases.  
This review will focus on the strategies for the systemic delivery of therapeutic 
nucleic acids targeting the CNS. Pathways and mechanisms of transport across the BBB 
which could be exploited for delivery are described, focusing in particular on smaller 
nucleic acids including ASOs and siRNA. Approaches used to enhance delivery including 
chemical modifications, nanocarrier systems, and cell-specific delivery are critically 
analysed. A comparison of the successes and failures reported for CNS delivery of ASOs 
versus siRNA highlights learnings, which will help identify future translational 
opportunities for a wider range of therapeutic nucleic acids. 
 
2. CHALLENGES FOR SYSTEMIC DELIVERY 
 The initial challenges faced by nucleic acids after systemic administration lie in 
the circulatory system. From the drug delivery point of view, RNA molecules have 
unfavorable physicochemical properties including a negative charge, high molecular 
weight and size, and serum instability. Naked RNA molecules are rapidly degraded by 
nucleases in biological fluids, which results in renal clearance and short circulation time 
in the blood (<10 minutes) 12. Degradation can stimulate the innate immune system, 
triggering inflammatory and other immune responses, and serum 
protein interaction.  This phenomenon, known as opsonisation, causes rapid uptake by the 
reticuloendothelial system (RES) (Figure 2). After systemic administration, phagocytic 
cells of RES, specifically the Kupffer cells in the liver and the splenic macrophages, can 
easily endocytose RNA oligonucleotides, resulting in higher concentrations in these 
organs following intravenous administration  13,26. 
In addition, the circulating nucleic acids must cross the vascular endothelial 
barrier to accumulate in the target tissue. The structure and permeability of the capillary 
endothelia vary across different organs and tissue types, making some tissues more 
accessible to therapeutics than others. For example, the liver and spleen are composed of 
fenestrated capillaries and discontinuous basement membranes exhibiting large inter-and 
intracellular gaps, which allows the easy diffusion of RNA into the tissue interstitium. 
The CNS capillaries, due to the BBB, exhibits non-fenestrated capillaries with dense 
intercellular junctional proteins (TJ and AJ) and a continuous basement membrane 




After reaching the target cell, the next challenge is cellular uptake of the nucleic 
acid therapeutics. The cellular membrane is made of negatively charged phospholipids 
and this charge is a barrier for RNA uptake. Moreover, the high molecular weight, large 
size, and hydrophilic nature of RNA molecules impede membrane permeability. As a 
result, the major mode of internalization is via endocytosis, whereby the molecules are 
internalized together with a component of the cell membrane 12. Finally, endosomal 
escape and release into the cytoplasm is a key problem that must be solved to ensure a 
safe delivery of RNA-based therapeutics and effective gene knockdown 11. 
 
 
Figure 2. Physiological barriers to systemic delivery of RNA-based therapeutics. After systemic 
administration, the therapeutic nucleic acid must avoid: interaction with bloodstream 
components, renal excretion, and uptake by phagocytes of the reticuloendothelial system (RES). 
Once at the targeted tissue, it must be internalized into the cell and escape from the endosome 
before degradation. 
 
In light of the challenges described above, generally, only small lipophilic 




small water-soluble molecules can simply cross BBB through the TJ and AJ, however, 
paracellular transport is generally limited (Figure 3(2)). Almost all other substances 
require certain endogenous transport systems to cross the BBB, such as transport proteins 
(carrier-mediated transport), absorptive-mediated transcytosis, or receptor-mediated 
transcytosis 28.  
Transport proteins (Figure 3 (3)) enable essential molecules such as glucose, 
amino acids, monocarboxylic acids, hormones, fatty acids, carbohydrates, nucleotides, 
inorganic ions, amines, choline, and vitamins to cross the BBB via substrate-specific 
transporters; e.g., GLUT1 for glucose and LAT1 for some amino acids 23. Adsorptive-
mediated transcytosis (Figure 3(4)), is triggered by electrostatic interaction between a 
positively charged substance, and the negatively charged membrane surface of the 
endothelial cells. Receptor-mediated transcytosis (Figure 3(5)) enables the transport of 
small and large molecules including hormones, growth factors, enzymes, and plasma 
proteins. Endothelial cells have a limited number of receptors on their surface; thus, this 
route is normally a saturable process 29,30. 
Via receptor-mediated transcytosis, a specific receptor binds to its ligand on the 
luminal side of the endothelium and carries it to the abluminal side via the formation of 
endocytic vesicles. These vesicles can be either clathrin- or caveolae-dependent 31. 
Importantly, the different nature of the endocytic vesicles will dictate the intracellular 
routes followed by the cargo prior to its delivery to the abluminal side (brain). Contrarily 
to the clathrin-dependent pathway, the caveolae-dependent pathway can bypass 






Figure 3. Schematic representation of the blood-brain barrier and the main transport routes 
for permeation and transport across the endothelium. (1) Small lipid-soluble agents can 
passively diffusive through the lipid bilayer. (2) Only small water-soluble molecules can diffuse 
through the intercellular spaces between endothelial cells. (3) The endothelium contains carriers 
for glucose, amino acids, nucleosides, purine bases, choline, and other substances. (4) Cationic 
molecules such as albumin and other plasma proteins are taken up by adsorptive-mediated 
transcytosis, which is consecutive of the endocytosis/exocytosis event. (5) Ligands such as insulin, 
transferrin,  cholesterol-containing particles, and most other protein hormones are taken up by 
specific receptor-mediated transcytosis. Once across the BBB, the compounds must diffuse 
towards the disease site and be taken up by the diseased cells. TJ: tight junction; AJ: adherens 
junction. 
 
The above-described different transport systems across the BBB have been 
exploited to deliver therapeutic drugs to the brain. Generally, targeting transporters or 
receptors to access the brain, involves creating complexes between the drug of interest 
and a receptor-targeting item. Such items can be the endogenous receptor/transporter 




proteins present in the brain endothelium can be targeted to deliver the drug of interest 
into the brain. An example for this would be the use of glycosylated nanocarriers that can 
cross via the GLUT1 receptor 33. One clear drawback is that many of these receptors, such 
as the GLUT receptors, are not exclusively expressed in the brain endothelium, which 
can lead to non-specific targeting. Clathrin-dependend transport has been also used for 
drug delivery into the brain, especially the transferrin receptor. Despite of being highly 
expressed in the brain endothelium, it is also expressed in other tissues throughout the 
body. Moreover, it is inefficient in delivering the cargo into the brain from the endothelial 
cytoplasm 34,35.  Caveolae-dependent transport has an important advantage in terms of 
intracellular trafficking of the cargo, as it does not involve the lysosomal pathway 32,36. 
In this context low-density lipoprotein receptor is a good candidate to target for drug 
delivery purposes. To do so, the two main strategies include protein corona-mediated 
targeting and ligand-based targeting 35. Both of these strategies are further detailed below. 
Finally, endothelial cells express several ATP-driven drug efflux pumps, such as 
P-glycoprotein (P-gp), multidrug related protein (MRP), and breast cancer resistance 
protein (BCRP) transporters, which provide an additional layer of regulation by actively 
excluding many hydrophobic molecules from the CNS 29,30. These efflux transporters 
constitute an important challenge for drug delivery into brain tissue, as they are known to 
greatly restrict brain permeability to a wide array of structurally diverse xenobiotics 37. 
Therefore, it is essential that these transporters are considered while assessing drug 
transport properties in preclinical studies. 
In summary, different approaches are being explored in order to overcome the 
limitations of each these routes of transport across the BBB. Further investigation will 
allow optimization of drug delivery into the brain. In the last years, researchers have 
designed carriers (e.g. nanoparticles (NPs)) to target diseased cells in the brain with high 
specificity by overcoming the BBB and with reduced toxic side effects 38. The main 
ligands target specific receptors on the BBB, as well as cell-specific markers on the 
diseased brain are discussed below. 
 
3. DESIGN AND DEVELOPMENT OF RNA-BASED THERAPEUTICS FOR 
SYSTEMIC DELIVERY  
Despite the promising potential of RNA-based therapeutics, delivery strategies are 
required for the successful translation of ASOs and siRNA into the clinic. There are two 




chemical modification of the ASOs/siRNA structure itself while preserving the molecular 
nature and activity of the nucleic acid. The other is the incorporation of the nucleic acids 
into a delivery system. Both strategies aim to enhance the safety and potency of the 
nucleic acid, resulting in selective and stable systems 39.  
The main approaches for the delivery of ASOs and siRNA therapeutics are 
summarized in Figure 4. To date, unformulated/naked and chemical modifications 
predominate for ASOs, while conjugates and nanocarrier systems have been more widely 
studied for siRNA.  
 
Figure 4. Main strategies for Central Nervous System delivery of antisense oligonucleotides 
(ASOs) and small interfering RNA (siRNA). Unformulated/naked and chemical modifications 
predominate for ASOs, while conjugates and nanocarrier systems have been more widely studied 
for siRNA.  
 
3.1 Chemical modifications 
A variety of chemical modifications have been developed to improve the physical 
and pharmacological characteristics of RNA-based therapeutics (Table 1), such as ASOs 
and siRNA. Alterations in the chemical structure of the nucleic acids are focused on either 
the backbone, the sugar group (ribose), or the nucleobases 39.  
Nucleic acids consist of nucleotides all with a common structure. Nucleotides 
incorporate ribose linked at the 1’ position to a nucleobase and the 5’ position to a 
phosphate group. These structures are connected via phosphodiester bonds formed at 3’ 
and 5’ carbon of the ribose and make up the strands of the nucleic acids. The phosphate 
linkage and ribose are easy targets for metabolic degradation. Therefore, chemical 




composition, siRNA and ASOs differ in their strand characteristics. siRNA consists of a 
double-strand and therefore leads to some restriction in the application of modifications 
due to duplex stability and interaction between siRNA and RISC complex 42. 
 
Table 1. Common chemical modifications used in RNA-based therapeutics  





Enhance nuclease stability 
Improve pharmacokinetics  
Sugar 
modifications 
2’ ribose modifications  
(2'-OMe, 2'-F, 2'-OME, cEt, 
LNA) 
Increase binding affinity to RNA  
Enhance stability against nucleases  
Decrease immune activation 
Nucleobase 
modifications 
5-methylcytosine Enhance RNA affinity 
Decrease pro-inflammatory properties  
Conjugations Biomolecules (antibodies, 
aptamers, peptides) 
 Hydrophobic derivatives  
Modulate protein binding 
Modulate tissue distribution 
 
Abbreviations: 2’-OMe, 2’-O-Methyl; 2’-F, 2’-Fluoro, 2’-MOE, 2’-O-Methoxyethyl; cET, 2’,4’-
constrained 2’-O-ethyl; LNA, Locked Nucleic Acid. 
 
3.1.1 Backbone modifications 
The chemistry of the backbone has the largest impact on the pharmacokinetics and 
pharmacodynamics properties of nucleic acids 41. Therefore, the replacement of the 
natural phosphodiester backbone by the inclusion of a more hydrophobic 
phosphorothioate (PS) was the first chemical modification implemented on nucleic acids.  
The PS modification replaces a non-bridging phosphate oxygen atom with a sulfur atom 
and has been extensively used to improve nuclease stability 43 of both - ASOs 44,45 and 
siRNAs 46.   
The PS-modified backbones increase resistance against nucleases in serum and 
tissues, and consequently prolonged circulation time. It promotes protein binding and thus 
supports interactions with albumin and other blood proteins thereby retarding renal 
clearance and ensuring that PS-oligonucleotide can reach the tissues. The PS-
modification is fully consistent with the RNase H activity 41,47–49. Following intravenous 
administration of single-stranded PS-modified oligonucleotides, the distribution phase 
from plasma to tissues ranges from a few minutes to a few hours followed by a prolonged 




do not bind extensively to plasma proteins and are quickly cleared by the kidneys, 
accumulating at lower levels in tissues 15,50.  
Similar backbone modifications include the replacement of non-bridging oxygen 
with boron (boranophosphate), nitrogen (phosphoramidate), or methyl 
(methylphosphonate) 42,43. Phosphoramidate and methylphosphonate are preferentially 
used in ASOs and were not intensively studied in siRNA, whereas boranophosphate is 
applicable for both nucleic acids 43. 
The replacement of the sugar-phosphate by the introduction of a peptide or 
morpholino structure leads to the elimination of the charge of the nucleic acid backbone, 
this modification is mostly used for ASOs. The phosphodiester linkages are either 
replaced with phosphorodiamidate (morpholino) or polyamide (peptide) linkages 39,47.  
As a result of neutralization, the nucleic acids lose the ability to mobilize RNase 
H 47,51,52. They gain protection against nuclease degradation but operate by translation 
inhibition through steric interference 52 and splice modification 47,51,52. On the contrary, 
the neutral character of morpholino- and peptide-modified ASOs impairs cellular uptake 
due to the decreased probability of interaction with negatively charged cell membranes. 
To compensate for this drawback two strategies have been investigated: firstly, the 
formulation into a lipid nanoparticle, or the conjugation with a peptide which functions 
as a targeting ligand, leading to receptor-mediated uptake 52. 
 
3.1.2 Sugar modifications 
An approach to reduce the immune activation of nucleic acids while further 
enhancing the nuclease resistance includes substituting the 2´-hydroxy group at the 
ribose. This approach includes modification with 2’-O-methyl (2’-OMe), 2’-fluoro (2’-
F), 2’-O-methoxyethyl (2’-MOE) groups, and bridged rings (2’,4’-constrained 2’-O-ethyl 
(cET), locked nucleic acid (LNA) 40,41. 
All 2’-OH-modifications, which can be applied to ASOs, can also be applied to 
siRNA, though with some restriction due to the mechanism of action of the siRNA. 
Modifications in siRNA can lead to impaired loading into the RISC complex, which 
decreases siRNA efficacy. 2’-OMe and 2’-F are the most commonly used modifications 
in siRNA 50. The naturally occurring 40,48 and therefore non-toxic 2’-OMe modification 
is only used in alternate bases in siRNA to maintain efficacy and simultaneously gaining 
resistance against recognition by the immune system and also enhanced nuclease 




The 2’-MOE modification is comparatively larger and therefore can only be 
applied at specific positions in the guide strand of the siRNA because of its negative 
impact on the silencing activity. Even in ASOs, 2’-MOE is mostly used in the so-called 
‘gapmer’ design (see section below) 48.  
The bridged 2’,4’-ring of ribose is one of the most complicated 2’-ribose 
modification involved in ASOs chemistry, especially in the design of gapmer ASOs 42, 
which comprises the binding of cET and LNA 48. This modification provides an increased 
binding affinity to target-mRNA 53 but is unable to recruit RNase H 47. Instead, it operates 
via alternative splicing or translational inhibition. A new type of oligonucleotide 
composition was investigated to regain the RNase H recruitment 52, this provides the basis 
for the development of gapmers 54. Gapmers contain a central unmodified region of 
nucleotides, flanked with 2’ modified nucleotides on each side 47,48. The unmodified 
region features RNase H activity 50, whereby the flanked regions only improve the 
binding affinity to target mRNA 41. This approach represents high nuclease resistance, 
low toxicity, and increased hybridization affinities to mRNA 42,48. 
 
3.1.3 Nucleobase modifications 
Compared to modifications of the backbone and sugar moieties, nucleobase 
modifications have not been used extensively for the stabilization of RNA-based 
therapeutics. Modifications to the nucleobases could create modified nucleosides 
metabolites that may be incorporated into native nucleic acids and interfere with the 
correct expression and maintenance of genetic material. There is, however, a notable 
exception - the C-5 methyl substitution on pyrimidine nucleobases (5-Methylcytosine, 5-
methylcytidine and 5-methyluridine/ribothymidine) 42,55.  The pyrimidine methylation  
has the effect of increasing the oligonucleotide melting temperature by ~0.5 °C per 
modification, and has been commonly incorporated into ASOs (e.g, those under 
development by Ionis Pharmaceuticals) 56,57. 
 The nucleobase modification can impact the nucleic acid activity in various ways: 
nuclease resistance, enhanced sequence selectivity to target mRNA, reduced off-target 
effects by preventing immune stimulation resulting in decreased pro-inflammatory 
characteristics 15,57 and more efficient gene activity 58,59. Interestingly, 5-methyl 
substitution decreases the activity of siRNA and is therefore not beneficial in this regard 




In summary, as described above, chemical modification is a promising approach 
to make nucleic acids a successful therapeutic modality to treat diseases including 
neurological disorders. However, despite the impressive preclinical potential of siRNA 
for treating brain diseases, most of the candidates, whether approved or in clinical trials, 
are ASOs. Currently, there are two FDA-approved ASOs: Nusinersen (also known as 
Spinraza™, ISIS 396443, ISIS-SMNRx, and ASO–10-27) and Eteplirsen (Exondys 
51™). Nusinersen is indicated to treat spinal muscular atrophy, a hereditary 
disorder linked to deletion or mutation of the survival motor neuron 1 gene located on 
chromosome 5q13. It has two chemical modifications, one on its backbone (PS) and 
another at its sugar units (2’-MOE) 60.  Eteplirsen is an ASO with phosphoroimidate 
morpholino modification at the backbone against Duchenne Muscular Dystrophy, a 
debilitating genetic disease characterized by the lack of functional dystrophin protein, 
which results in progressive lethal skeletal muscle degeneration 61. There are also other 
candidates in Phase 3 clinical trial; Trabedersen is an ASO from Isarna therapeutics 
design with a simple PS-modification tested against glioblastoma 61, and Tominersen is a 
gapmer-RNA modified with 2’-MOE PS developed for the treatment of Huntington 
Disease 62,63. Imetelstat, a  second glioblastoma product, contains N3’-PS thio-
phosphorimidate with a covalently linked C16 lipid moiety at the 5’ end 64. 
 
3.2 Nanocarrier systems 
Parallel to the development of chemically modified nucleic acids, researchers 
have also been working on nucleic acid carrier systems. NPs have a proven track record 
as efficient carriers for systemic nucleic acid delivery including brain delivery (Table 2). 
Formulations include lipid-based NPs (LNPs), polymeric NPs, and lipid-
polymer hybrid NPs, and modified cyclodextrins (CDs). These NPs have demonstrated 
remarkable properties such as the ability to cross multiple biological barriers, protect 
target genes against nuclease degradation, improved pharmacokinetic profile by 
preventing renal excretion and RES clearance, enhanced stability in physiological 
solutions, and delivery to target specific tissues or cells 65–68. Recently, exosomes have 
also emerged as a new delivery vehicle for siRNA, ASOs, and small molecules to the 
brain 69–71. The characteristics of nanocarrier systems and examples of their formulation 





Table 2. Selected examples of nanoparticle-based RNA formulations for in vivo brain 
delivery via systemic administration. 













C57 BL/6 ataxin-3 
[Q69]-transgenic  





Transgenic zebrafish - 74 


















Nude U87 xenograft mice LRP-1 77 























Abbreviations: CD, cyclodextrin; GOLPH3, Golgi phosphoprotein 3; LRP-1, low density lipoprotein 
receptor-related protein 1; nACh, Nicotinic acetylcholine receptor; NPs, nanoparticles; PBAE, poly(β-
aminoester); RRM2, ribonucleotide reductase subunit M2;  RVG, rabies virus glycoprotein; SOD, 
superoxide dismutase I 
 
3.2.1 Lipid-based NPs 
Over the past decades, the delivery approach that is both most extensively used 
and most clinically advanced is to complex oligonucleotides with cationic lipids thus 




Onpattro (Patisiran), was approved by FDA and launched by Alnylam. Onpattro is 
formulated as a LNPs to delivery siRNA targeting transthyretin (TTR) into hepatocytes 
for the treatment of hereditary TTR-mediated amyloidosis in adults 82. This drug 
represents the dawn of the RNA nanomedicine era and it further accelerated the 
development of nucleic acid-loaded LNPs for various therapies. Recently, 
BioNTech/Pfizer and Moderna encapsulated their mRNA vaccines against COVID-19 
using LNPs 83. 
Lipid-based NPs include liposomes, solid lipid NPs, and nanostructured lipid 
carriers. These nanocarrier systems are composed of cationic (ionizable) lipids that bind 
DNA or RNA molecules, neutral helper lipids that increase transfection efficiency, and a 
nucleic acid vector encoding for the target gene 84. Sometimes an additional targeting 
ligand is also incorporated to enable selective delivery to targeted cells after systemic 
administration. Generally, the basic structure of the cationic lipid employed for gene 
delivery consists of three domains: a hydrophilic headgroup (monocation or polycation, 
linear or heterocyclic) attached, via a linker bond, to a hydrophobic tail group (cholesterol 
or aliphatic) 85. The positively charged headgroup is not only responsible for the nucleic 
acid complexation but also affects NPs characteristics such as the surface charge. A large 
number of cationic headgroup structures have been investigated for application in gene 
delivery, selected examples are shown in Table 3 84. 
 
Table 3.  Cationic lipids that have been used in lipid-based NPs. 
Amino Lipids  Optimized ionizable lipids Lipidoids 











Multivalent ionizable: DOGS Dlin-MC3-DMA  
Cholesterol derivatives: DC-Chol; 
GL67 
  
Abbreviations: DC-Chol, 3β-(N-(N’, N’-dimethylaminoethane)carbamoyl)cholesterol; DLinDMA, 1,2-
dilinoleyloxy-3-dimethylaminopropane; DMRIE, N-(2-hydroxyethyl)-N,N-dimethyl-2,3-
bis(tetradecyloxy)-1-propanaminium bromide; DODAP, 1,2-Dioleoyl-3-dimethylammonium-propane; 
DODMA, 1,2-dioleyloxy-3-dimethylaminopropane; DOGS, N,N-dioctadecylamidoglycylspermine; 
DOTAP, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate; DOTMA, N-[1-(2,3-





Although permanently charged cationic lipids have proven useful for in vitro 
transfection purposes, their utility in vivo is limited due to reduced transfection efficiency 
and cellular toxicity. The toxicity is normally associated with higher charge ratios 
between the cationic lipids and the nucleic acids as well as the dose administered 86. To 
overcome this issue, ionizable cationic lipids such as DODAP were developed with 
apparent pKa values between 6 and 7 87. This pKa ensures an efficient encapsulation of 
nucleic acid polymers at acid pH, a near neutral or mildly charged surface in the 
circulation at physiological pH, and a high positive surface charge at the acid environment 
of the endosome, which destabilized the NPs to release their RNA cargo 88.  
The rational design of the linker and the tail group is another strategy to enhance 
the efficacy of the formulation. The linker affects not only the global pKa of ionizable 
lipids but also the size, flexibility for charge presentation, and biodegradability of the 
delivery system. The lipid properties of the tail group such as the degree of saturation, 
chain length, and substitution, also affect the transfection efficiency 84.  
Several groups have encapsulated nucleic acids into LNPs for brain targeted gene 
delivery using the aforementioned ionizable cationic lipids 73,89–91. Cohen et al. developed 
LNPs composed of the ionizable cationic lipid DLin-MC3-DMA, helper lipids Distearoyl 
phosphatidylcholine (DSPC), and cholesterol, using Dimyristoyl glycerol (DMG) PEG 
(DMG-PEG), and distearoylphosphatidylethanolamine (DSPE)-PEG amine as linkers. 
The formulation was further functionalized with hyaluronan to deliver PLK1-siRNA to 
glioma cells. The authors observed a robust silencing of 80% in PLK-1 expression and 
prolonged survival (+60%) of a U87 xenograft mouse model 89. Conceição and co-authors 
use DODAP, cholesterol, and DSPC to formulate liposomes. The liposomes were further 
functionalized with the brain-targeting rabies virus glycoprotein (RVG)29–nona-arginine 
and conjugated to DSPE-PEG-Maleimide. Promising results were observed in two 
transgenic mouse models of Machado-Joseph disease (MJD), also called spinocerebellar 
ataxia Type 3 (SCA3), upon intravenous administration of siRNA targeting mutant 
ataxin-3 mRNA. The efficient silence of mutant ataxin-3 reduced the neuropathology and 
motor behaviour deficits of both mice strains 73. 
A further liposome-mediated delivery has been developed (DCL64) composed of 
dipalmitoyl-phosphatidylcholine, cholesterol, and poloxamer L64. Intravenous 
administration of DCL64 formulation resulted in the interaction with low-density 




oligonucleotides in Purkinje cells of mouse cerebellum 92.  In another study, cationic 
liposomes with angiopep-2, a specific ligand of LRP-1, were used to deliver Golgi 
phosphoprotein 3 (GOLPH3)-siRNA for glioma treatment. Using an U87-GFP-
Luciferase-bearing BALB/c mouse model, the authors demonstrated that the liposomes 
delivered GOLPH3-siRNA specifically to glioma and effectively inhibited glioma growth 
72. 
 
3.2.2 Polymeric nanoparticles 
Polymeric NPs provide another widely used strategy for nucleic acid delivery. 
Although they have not progressed clinically to the same degree as LNPs, polymeric NPs 
have shown desirable features such as biological safety (low immunogenicity, absence of 
mutagenesis), chemical versatility, facile synthesis, and low production costs 50,93,94.  
At an early stage, natural polymers such as polysaccharides (chitosan, CDs, 
alginate) and proteins (gelatin, albumin) were investigated as sustained gene delivery 
vectors, however, they exhibited low transfection efficiency. Therefore, in an effort to 
increase transfection efficacy many synthetic polymers have been developed including 
poly(ethyleneimine) (PEI), poly(lactic acid) (PLA), poly(L-glutamic acid) (PLGA), 
poly(L-lysine) (PLL), poly-ε-caprolactone (PCL), poly(β-aminoester) (PBAE), poly(2-
(dimethylamino) ethyl methacrylate) (PDMAEMA), and the dendrimer poly(amido-
amine) (PAMAM). Synthetic polymers have been used alone or in combination with 
natural polymers in the preparation of NPs or incorporated into sustained-release systems 
such as hydrogels, nanospheres, microspheres, and scaffolds 94–96. Regardless, 
PEGylation, functionalization with targeting ligands, or modification by introducing 
histidine residues in their backbones is still necessary to improve the transfection 
efficiency and circulation times of polymeric NPs 97. 
The most commonly explored compounds for brain gene delivery include the 
polymers PEI, PBAE, and PLGA, and the dendrimer PAMAM 96,98,99. However, without 
surface modification with target ligands, polymeric NPs have a limited capacity to cross 
the BBB in sufficient amounts for therapeutic application. In a recent study, GLUT-1 
targeted polymeric NPs (glycosyl-PEG-PLL modified with 3- mercaptopropyl amidine 
and 2-thiolaneimine) were designed for the delivery of ASOs across the BBB. The 
nanocarrier demonstrated efficient brain accumulation 1 h after intravenous 
administration and exhibits significant knockdown of a target long non‐coding RNA in 




3.2.3 Lipid-Polymer hybrid nanoparticles 
Lipid-polymer hybrid NPs for gene delivery (lipopolyplexes) combine the 
desirable features of both lipids and polymeric NPs with high in vivo transfection 
efficiencies, improved colloidal stability, and reduced cytotoxicity 97.  As shown in Figure 
5, this type of nanostructure generally has a polymeric core containing the therapeutic 
agents to be delivered, and a lipid shell that may either be a monolayer or bilayer. In some 
cases, an additional outer PEG layer and target ligands are further coated onto the lipid 
surface 100. 
An efficient delivery system based on DOTAP, PLGA, DSPE-PEG2000, and 
Angiopep-2 was developed to co-deliver Gefitinib and GOLPH3-siRNA across the BBB. 
The authors demonstrated that Angiopep-2 improved siRNA delivery to the brain tumor, 
downregulated GOLPH3, and EGFR expression after intravenous administration, and 
increased the median survival of the animals by 30% compared to non-treated controls 77. 
 
Figure 5. Schematic representation of a lipid–polymer hybrid nanoparticles (NPs). The NPs 
comprises of a polymeric core containing a payload (siRNA or ASOs) surrounded by a lipid shell. 
Note: An additional outer PEG layer can be added and conjugated with targeting moieties such 







CDs are a family of naturally occurring cyclic oligosaccharides obtained through 
bacterial digestion of starch, which are composed of glucose units linked by α-1,4-
glycosidic bonds.  The most common forms are α, β‐, and γ‐CDs, which consist of six, 
seven, and eight D‐glucopyranose units, respectively 101. CDs have a truncated cone-
shaped appearance with upper (narrow, primary) and lower (wide, secondary) rims. The 
core is relatively hydrophobic due to the presence of CH groups and glycosidic oxygens, 
whereas the hydrophilicity at the cavity entrances (rims) are attributed to primary and 
secondary hydroxyl functional groups (-OH) (Figure 6) 102. Such unique structure results 
in an ‘inner-outer’ amphiphilic characteristic enabling the CDs to encapsulate organic,  
and inorganic molecules via host-guest interaction 101. Due to these features and excellent 
biocompatibility and low toxicity, CDs have been profusely exploited by the 
pharmaceutical industry to improve the solubility of hydrophobic compounds, and/or to 
improve stability, bioavailability, and delivery of hydrophilic as well as lipophilic drugs, 
through biological membranes 101,103,104. 
 
Figure 6. Schematic illustration of the 3D structure of cyclodextrin (CD). The CD comprises 
glucose units linked by α-1,4-glycosidic bonds and has a hydrophobic central cavity and a 
hydrophilic outer surface. 
 
 In the last decade, attention has been focused on the potential application of 
modified CD as gene delivery systems 105–107, especially for treating brain diseases 108–
111. Modified amphiphilic β-cyclodextrins were used to deliver Huntingtin (HTT) targeted 
siRNAs to in vitro and in vivo models of Huntington disease. The formulation was stable 
in cerebrospinal fluid with limited toxicity. Sustained knockdown effects were observed 




Besides its potential as a carrier, CDs can also act as therapeutic agents to treat 
neurodegenerative disorders exhibiting impaired cholesterol metabolism (e.g., Niemann-
Pick type C (NPC), Alzheimer’s, Huntington’s, and Parkinson’s diseases). CDs can 
directly interact with the BBB endothelial cells and modify cell membrane composition 
due to their ability of lipid extraction that directly influence cholesterol trafficking and 
homeostasis 104. Two clinical trials are currently underway to evaluate the safety, 
pharmacokinetic and pharmacodynamic assessments of systemic IV administration of 
hydroxypropyl-beta cyclodextrin to NPC patients 112. 
 
3.2.5 Exosomes 
Exosomes have recently emerged as a novel delivery system for biological 
therapeutics including siRNAs, ASOs, antibodies, and small molecules, especially those 
targeted to the brain tissue that require passage through the BBB 69–71. Exosomes are 
extracellular nanovesicles (40-120 nm) produced by almost every cell type, including B 
cells, T cells, dendritic cells, macrophages, neurons, glial cells, astrocytes, stem cells, and 
most tumour cell lines. They are generated mainly when multivesicular bodies fuse with 
the plasma membrane and release their content (exosomes) to the extracellular milieu. 
After exocytosis, exosomes are taken up by the recipient cells, and release their cargo 
(e.g., nucleic acids, enzymes, peptides, lipids), which can mediate many physiological 
and pathological process 113,114. 
Owing to desirable properties such as size, lipid membrane bilayer structure and 
functional properties, exosome-based delivery has multiple advantages over other 
delivery systems. For instance, exosomes are stable in the bloodstream enabling 
prolonged circulation. They are capable of carrying soluble drugs due to their hydrophilic 
core. Because exosomes are nanosized and are isolated from specific cells, they have a 
high capacity for overcoming various biological barriers, possess a natural targeting 
capacity, and thus have fewer off-target effects 71,113. 
Pioneering work on exosome-mediated systemic CNS delivery of siRNA was 
initiated by Alvarez-Erviti and co-workers in 2011. Murine self-derived dendritic 
exosomes targeted with the neuron-specific RVG peptide and the exosomal membrane 
protein Lamp2b delivered GAPDH siRNA and BACE1 siRNA to neurons, microglia, 
oligodendrocytes in the mouse brain after intravenous administration.  The exposure to 
RVG-decorated exosomes resulted in strong mRNA and protein knockdown of BACE-1 




exosome (T7-exo) was produced by incorporation T7, a transferrin receptor-binding 
peptide, into the exosome membrane as a fusion protein of T7 and Lamp2b. The T7-exo 
was evaluated as a carrier for brain-targeted delivery of antisense miRNA 
oligonucleotides against miR-21 (AMO-21), using RVG exosomes/AMO-21 as a control. 
Both brain-targeting ligands RVG and T7 increased the targeted trafficking of exosomes 
to the brain and reduced  miR-21 levels in the glioblastoma by ~80% and ~60%, 
respectively compared to the control group 80. 
 
3.3 Nucleic acid conjugates 
Although significant progress has been made with chemical modifications and 
nanocarriers systems, brain-specific targeting is essential for an improved therapeutic 
effect of RNA-based therapeutics. To overcome the hurdles of selective CNS delivery of 
RNA-based technologies, reliable transport ligands have been linked to nucleic acids 
whether presented in naked form, as a chemical conjugate, or in association with a 
nanocarrier. Covalent conjugation of specific molecules to nucleic acids is a promising 
therapeutic approach to improve cellular uptake as well as pharmacokinetic properties 
40,115. However, conjugates can be applied to relatively small nucleic acid molecules such 
as ASOs and siRNA, but it is difficult to apply to large macromolecules such as mRNA, 
plasmid DNA, and CRISPR/Cas9. This method includes forming conjugates with (1) 
biomolecules capable of specifically binding receptors to the cell membrane such as 
folate, antibodies, aptamers, some peptides, and carbohydrates; (2) molecules capable of 
cell penetration by natural transport mechanisms (e.g., cholesterol and vitamins), or (3) 
molecules capable of interacting non-specifically with the cell membrane such as 
positively charged compounds 116.  
These ligands target specific receptors on the BBB, as well as cell-specific 
markers on the diseased brain. The most widely studied ligands are transferrin, insulin, 
and low-density lipoprotein (LDL) receptors. Additional ligands that may have enhanced 
BBB specificity include aptamers, antibodies, peptides, and lipophilic derivatives 116–118. 
The conjugation of siRNA (naked form) or NPs containing siRNA with ligands for 






Nucleic acid aptamers are short, single-stranded DNA or RNA oligonucleotides 
that assume unique tri-dimensional structures capable of specific molecular recognition 
of their cognate target. Generated through a process named systematic evolution of 
ligands by exponential enrichment (SELEX), aptamers demonstrate high affinity and 
specificity similar to the way that monoclonal antibodies bind to antigens 119.  Since 
aptamers can be synthetized against any target, they can potentially be used for the 
specific delivery to any organ, tissue or cell where the desired target would be expressed 
120. Moreover, they have some crucial advantages, such as low immunogenicity and 
toxicity, prolonged stability, and low production variability 121. 
Aptamers have been identified as highly promising agents for brain-targeted 
therapy due to the ability of some aptamer conjugates to cross the BBB 122–124. A 
bifunctional aptamer targeting the transferrin receptor (TfR) and the epithelial cell 
adhesion molecule (EpCAM), a cell surface marker overexpressed on several solid 
tumors has been developed. Since transferrin receptors are highly expressed on the 
surface of the BBB, TfR-EpCAM aptamer can binds to transferrin receptors on the 
surface of endothelial cells to be transported across the BBB, and therefore, deliver the 
payload to EpCAM-positive cells. In this study, the resulting bi-specific TfR-EpCAM 
aptamer, showed enhanced binding affinity and was able to effectively transcytosing 
through an in vitro BBB model, and also in healthy NOD/SCID mice following a single 
intravenous injection (40 nmol/kg) 123.  
In recent years, aptamers have been transformed into multifunctional agents for 
the selective delivery of siRNAs, microRNA, small hairpin RNAs, and ASOs 121, the so-
called aptamer-chimeras. Aptamer-siRNA chimeras may offer dual-functions, in which 
the aptamer inhibits a receptor function, while the RNAi internalizes into the cell to target 
a specific mRNA. Using a co-culture model of human endothelial cells, astrocytes, and 
pericytes, it has been shown that both GL21.T and Gint4.T aptamers, either as single 
molecules or conjugated to microRNA-137 or anti-microRNA-10b can cross the BBB. 
The RNA aptamers, GL21.T and Gint4.T, were able to bind with high affinity and inhibit 
the intracellular signaling of tyrosine kinase receptors (RTKs) Axl and the platelet-
derived growth factor receptor β (PDGFRβ), respectively. These receptors are frequently 
highly expressed in glioblastoma stem-like cells and are associated with 
neovascularization 124. A Gint4.T aptamer has successfully delivered STAT3 siRNA 
(Gint4.T-STAT3) to glioblastoma cells resulting in the silencing of STAT3 in 




Gint4.T-STAT3 reduced tumour growth and angiogenesis in vivo in a 
subcutaneous xenograft mouse model after repeated systemic injections 125. 
 
3.3.2 Antibodies 
   Monoclonal antibodies (mAbs), which act as a molecular ‘Trojan horse’, have 
been adopted to deliver large molecules across the BBB. The receptor specific mAb 
penetrates the BBB via transcytosis mediated by specific receptors on endothelial cells, 
commonly the insulin and transferrin receptors 126. For example, OX26 (anti-rat TfR 
monoclonal antibody), R17-217 and 8D3 (both anti-mouse TfR monoclonal antibody), 
and 83-14 (anti-human insulin receptor) have all been investigated 127,128. 
The ability of a mAb against the human insulin receptor (HIRMab) combined with 
avidin-biotin technology successfully delivered siRNA across the BBB in an in vivo brain 
cancer model. Intravenous administration of the antibody-siRNA conjugate led to an 
efficient (69−81%) suppression in luciferase gene expression 129. Following the same 
principle, antibodies against antigens expressed on glioblastoma stem cells (CD44 and 
EphA2) were conjugated to chemically modified ASOs against renal cell carcinoma 
(DRR), also called FAM107A, a genetic driver of glioblastoma invasion. The therapeutic 
conjugate was successfully internalized and reduced DRR/FAM107A expression in 
patient-derived glioblastoma stem cells 130. 
Despite decades of development, the use of antibodies remains limited due to the 
need for sophisticated production and purification equipment leading to high costs. A new 
generation of optimized antibodies including antibody fragments or diabodies are now 
emerging to tackle this limitation, but complex manufacturing processes remain a 
challenge 120. 
 
3.3.3 Cell-penetrating peptides  
  Cell-penetrating peptides (CPPs) are short peptidic sequences, generally with 5-
30 amino acids, which facilitate drug or CPPs/cargo complexes to translocate across the 
cellular membrane. CPPs are classified into two categories: (1) Based on the origin of 
peptides (synthetic, chimeric, protein-derived peptides); and (2) Based on the 
physicochemical properties (cationic, amphipathic, and hydrophobic) 131,132. These short 
peptides are ligands for specific receptors that facilitate cell internalization by endocytosis 




 Several BBB shuttle peptides with increasing efficiency and versatility have been 
reported including Angiopep-2, Apolipoprotein (Apo) B, ApoE, Peptide-22, THR, 
Leptin30, MiniAp-4, RVG29, RVG-9R, GSH, G23, TAT (47–57), and octa-arginine (R8) 
134,135. The short peptide RVG, which is known to specifically bind to acetylcholine 
receptors in neuronal cells, was the first CPP used in the transport of oligonucleotides 
into healthy mouse brains. Intravenous administration of RVG-9R siRNA complexes to 
wild-type Balb/C mice induced a significant reduction in both mRNA and protein levels 
of Cu-Zn superoxide dismutase (SOD1)  in the brain 136. Examples of other studies 
designed to deliver nucleic acids into the brain using RVG constructs have been discussed 
in detail above 73,79,80. However, it is unclear how RVG mediated transport into the brain 
since the receptors are localized in neurons and not at the BBB endothelium. 
As a further demonstration of CPPs delivery potential, Angiopep-2 modified 
PLGA NPs have successfully co-delivered doxorubicin and epidermal growth factor 
receptor (EGFR) siRNA for glioma therapy. This delivery system was capable of 
penetrating the BBB in vivo, resulting in extended survival of the glioma-bearing mice 
and cell apoptosis in the glioma tissue 137. 
 
3.3.4 Lipophilic derivatives 
Lipophilic molecules are often conjugated to oligonucleotides for delivery 
purposes. To date, lipophilic conjugates have been used for the delivery of both single- 
and double-stranded RNAs 138. The concept behind conjugation with these molecules 
involves naturally occurring cell membrane transport mechanisms. More specifically, 
oligonucleotides modified with cholesterol are recognized by high- and low-density 
lipoproteins (HDL and LDL, respectively) and internalized via cholesterol binding 
receptors 133. Additionally, the addition of these lipid moieties to oligonucleotides 
increases the lipophilicity of the nucleic acids and enhances their permeability across the 
cell membrane 116. 
Conjugation of siRNA with cholesterol, fatty acids, and vitamins (with or without 
a phosphocholine polar head group) have been shown to modulate siRNA tissue 
distribution and silencing activity in vivo 139,140. In general, lipid-conjugated siRNAs 
primarily accumulate in clearance tissues (liver, kidney, and spleen). Higher lipophilic 
siRNAs preferentially bind LDL and distribute to the liver, whereas less lipophilic 
compounds bind to HDL in serum and accumulate in kidneys. No perfect correlation 




Regarding the brain, the degree of distribution is strongly and inversely correlated 
with the hydrophobicity 141. Although highly hydrophobic cholesterol-conjugated 
modified siRNAs (Chol-hsiRNAs) presented limited spread from the site of injection 
after intrastriatal injection, both docosahexaenoic acid (DHA)-conjugated, hydrophobic 
siRNA (DHA-hsiRNA) and phosphocholine-containing DHA-hsiRNA conjugate (PC-
DHA-hsiRNA) diffused to other brain regions further away from the striatum and induced 
70-80% silencing at both mRNA and protein levels 142,143.  
 
3.3.5 Protein corona (endogenous ligands) 
Upon systemic administration, NPs encounter serum components, such as 
proteins, in the biological fluids resulting in the formation of a protein corona on the 
surface. Although protein corona formation has been associated with undesirable effects, 
recent studies suggest that corona-mediated targeting by controlling the function of target 
plasma proteins on nano-surface may provide a more specific drug delivery 32,144–146. 
With regard to the brain targeting, apolipoproteins play a key role. They are involved in 
the intercellular transport of insoluble lipids to various cell types, which are taken up via 
specific apolipoprotein-recognizing receptors (e.g., LDL receptor and scavenger receptor 
class B type I (SR-B1))) expressed in several tissues and in the brain 147. For instance, 
Zhang et al. obtained a successful corona-mediated brain-targeting using a liposomal 
system loaded with doxorubicin and functionalized with a peptide derived from the 
amyloid -protein (Aβ1-42). When exposed to biological milieu, this peptide specifically 
interacts with the lipid-binding domain of the brain targeting apolipoproteins (i.e, ApoA1, 
ApoE, and ApoJ), resulting in the exposure of their receptor-binding domain. The 
reengineered liposomes demonstrated high brain-targeting capacity and improved anti-
cancer effects compared to non-target plain liposomes 145. Using a different approach, 
lipid NPs have been pre-functionalized with ApoE4 before systemic administration. This 
strategy increased NPs translocation into brain parenchyma, and exhibited a 3-fold 
improvement in brain accumulation compared to undecorated NPs 146. 
Despite these promising results, there is no available data concerning the 
exploitation of corona proteins for systemic delivery of nucleic acid. However, lessons 
learned from these studies could offer further insights into formulations designed for 
targeted delivery of nucleic acids to the brain. 
 




Currently, there are a large number of preclinical studies focusing on the delivery 
of siRNA-based therapeutics into the brain. Although these drugs have not been yet 
reached clinical trials, the successful delivery of siRNA to non-CNS tumour tissue using 
nanoparticle-based delivery systems following systemic administration has been 
demonstrated in multiple trials, providing proof-of-concept for RNAi-based therapeutics 
in humans 148. Two non-viral siRNA drugs namely Onpattro (Patisiran) and Givlaari™ 
(Givosiran), discussed in section 3.2.1, have already reached the market and there are 
some other siRNA-based drugs in the pipeline for approval in the coming years 149.  
Almost two decades after the discovery of RNAi therapeutics, several challenges 
have limited the usefulness of siRNA in clinical trials for brain delivery 8. To date, the 
main obstacles are delivery, limited diffusion/distribution, and durability (Figures 2 and 
3). After injection directly into the brain, siRNA shows effective silencing for only a short 
period and remains regionally restricted to cells near the injection site. Similarly, after 
injection into the spinal cord, siRNA does not penetrate broadly into the brain 
parenchyma, and requires several weeklong continuous perfusions to achieve efficacy. 
On the other hand, ASOs is effective for several weeks after a single intrathecal dose 150. 
These and other challenges, such as clinical trial design and commercial considerations, 
have limited the usefulness of siRNA therapeutics and will require further optimization 
to produce successful drugs for brain disease therapy. With the increase in research 
addressing these challenges, and the recent emergence of siRNA-based drugs in the 
market, the hope is that the application of siRNA-based therapeutics for the treatment of 
neurological diseases will also be exploited in clinical settings in the near future. 
Although systemic administration is more acceptable for patients compared to 
direct brain injection, this is not a common route of administration since nucleic acids do 
not cross the BBB after systemic administration. To simplify the delivery problem, drugs 
have been designed for administration directly into the brain and/or spinal cord. However, 
there are concerns regarding technical complications and the risks from highly invasive 
neurosurgery for patients. The complications are associated with the inaccurate insertion 
of the catheter, management of the device (including refills of the drugs), the possibility 
of an allergic reaction or rejection, infections, side effects and tissue damage with each 
local administration 151. Thus, safe and systemic delivery is the key focus in the 
development of novel nucleic acid delivery systems targeting the CNS. 
The recent approval by the US Food and Drug Administration (FDA) of two ASO-




Exondys 51™) and spinal muscular atrophy (Nusinersen, Spinraza™), has opened a new 
era in nucleic acid-based therapeutics for neurodegenerative diseases 10,152. To date, more 
than 100 ASOs are in preclinical development 153. Table 5 summarizes some ASO-based 
therapeutics that have advanced from the bench to the clinical stages.  The application of 





Table 5. ASO-based therapeutics for the treatment of brain disease that are FDA-approved or currently in clinical trials 
Drugs Disease Route  Status Sponsor NCT number 
ASOs      
IONIS 
MAPTRx 
Alzheimer Disease Intrathecal Phase 1 Ionis Pharmaceuticals NCT03186989 








Intrathecal Phase 1/2 Wave Life Sciences  NCT03225846 
Imetelstat Glioblastoma Brainstem tumors Intravenous  Phase 2-terminated Geron NCT01836549 
Tominersen1 Huntington Disease Intrathecal Phase 3 – recruiting Roche 
NCT03842969 
NCT03761849 
Trabedersen Glioblastoma Intratumoral Phase 3-terminated Isarna therapeutics NCT00761280 
Eteplirsen 
(Exondys 51™) 
DMD Intravenous FDA approved Sarepta Therapeutics - 
Nusinersen 
(Spinraza™) 
Spinal muscular atrophy Intrathecal FDA approved Biogen - 
Abbreviations: ASOs, antisense oligonucleotides; DMD, Duchenne Muscular Dystrophy. NCT: ClinicalTrials.gov identifier number. Data were collected 




5. FUTURE DIRECTIONS  
 Targeted gene modification via gene-editing tools (ZFNs, TALENs, and 
CRISPR/Cas9) has been emerging as a new therapeutic option for the treatment of 
neurodegenerative diseases 154,155. However, there are still relevant drawbacks that need 
to be overcome before their clinical implementation. The major challenge is increasing 
the specificity and efficiency by decreasing the off-targets side effects. Furthermore, these 
components are more challenging to deliver, especially to the brain, due to the complexity 
and high molecular weight11,156. It is anticipated that research in gene editing will continue 
and advance significantly in the coming years. 
A lesson learned from the research performed to date is that delivery tools do not 
necessarily adapt to all applications. The gene therapy approaches developed thus far have 
their own advantages and limitations and, therefore, choosing the best tool largely 
depends on the situation and clinical need. 
 
6. CONCLUSIONS 
This review highlighted the chemical modifications and nanocarriers systems that 
are currently under investigation for ASOs and siRNA delivery to the brain.  There are 
many opportunities to optimize the formulation design to allow for systemic delivery.  A 
combination strategy for delivery including chemical modification in tandem with a smart 
delivery system designed to achieve stability in the circulation, permeability across the 
BBB, diffusion to the diseased site, and specific uptake by the diseased cells may help 
the translation of these therapeutics for neurodegenerative diseases. 
In summary, the past two decades have seen an exponential increase in RNA-
based therapies. Several clinical trials have been approved, are ongoing, or completed, 
with successful launches worldwide, however, RNAi has not yet achieved its full 
therapeutic potential. It is expected that new RNA-based medicines capaable of reaching 




This publication has emanated from research supported in part by a grant from 
Science Foundation Ireland (SFI) and the European Regional Development Fund (ERDF) 
under grant number 13/RC/2073_2.  AK acknowledges funding from SFI under Grant 








(1)  Carroll, W. M. The Global Burden of Neurological Disorders. Lancet Neurol. 2019, 18 (5), 418–
419. https://doi.org/10.1016/S1474-4422(19)30029-8. 
(2)  DiLuca, M.; Olesen, J. The Cost of Brain Diseases: A Burden or a Challenge? Neuron 2014, 82 
(6), 1205–1208. https://doi.org/10.1016/j.neuron.2014.05.044. 
(3)  Li, M.; Snider, B. J. Gene Therapy Methods and Their Applications in Neurological Disorders. In 
Gene Therapy in Neurological Disorders; Li, M., Snider, B. J., Eds.; Elsevier Inc., 2018; pp 3–
39. https://doi.org/10.1016/B978-0-12-809813-4.00001-6. 
(4)  Duarte, F.; Déglon, N. Genome Editing for CNS Disorders. Front. Neurosci. 2020, 14, 1–20. 
https://doi.org/10.3389/fnins.2020.579062. 
(5)  Han, Z. Gene Therapy Using Genomic DNA: Advances and Challenges. In Gene Therapy in 
Neurological Disorders; Li, M., Snider, B. J., Eds.; Elsevier Inc., 2018; pp 63–80. 
https://doi.org/10.1016/B978-0-12-809813-4.00003-X. 
(6)  Roovers, J.; de Jonghe, P.; Weckhuysen, S. The Therapeutic Potential of RNA Regulation in 
Neurological Disorders. Expert Opin. Ther. Targets 2018, 22, 1017–1028. 
https://doi.org/10.1080/14728222.2018.1542429. 
(7)  Sheridan, C. Billion-Dollar Deal Propels RNAi to CNS Frontier. Nat. Biotechnol. 2019, 37, 699–
706. https://doi.org/doi.org/10.1038/s41587-019-0185-0. 
(8)  Zheng, M.; Tao, W.; Zou, Y.; Farokhzad, O. C.; Shi, B. Nanotechnology-Based Strategies for 
SiRNA Brain Delivery for Disease Therapy. Trends Biotechnol. 2018, 36 (5), 562–575. 
https://doi.org/10.1016/j.tibtech.2018.01.006. 
(9)  Chery, J. RNA Therapeutics: RNAi and Antisense Mechanisms and Clinical Applications. J. 
Postdr. Res. 2016, 4 (7), 35–50. https://doi.org/10.14304/surya.jpr.v4n7.5. 
(10)  Watts, J. K.; Brown, R. H.; Khvorova, A. Nucleic Acid Therapeutics for Neurological Diseases. 
Neurothera 2019, 16, 245–247. https://doi.org/10.1007/s13311-019-00736-1. 
(11)  Dowdy, S. F. Overcoming Cellular Barriers for RNA Therapeutics. Nat. Biotechnol. 2017, 35 (3), 
222–229. https://doi.org/10.1038/nbt.3802. 
(12)  Wang, J.; Lu, Z.; Wientjes, M. G.; Au, J. L. Delivery of SiRNA Therapeutics : Barriers and 
Carriers Delivery of SiRNA Therapeutics : Barriers and Carriers. AAPS Journal, 2010, 12 (4). 
https://doi.org/10.1208/s12248-010-9210-4. 
(13)  Xu, C.; Wang, J. Delivery Systems for SiRNA Drug Development in Cancer Therapy. Asian J. 
Pharm. Sci. 2015, 10 (1), 1–12. https://doi.org/10.1016/j.ajps.2014.08.011. 
(14)  Watts, J. K.; Corey, D. R. Gene Silencing by SiRNAs and Antisense Oligonucleotides in the 
Laboratory and the Clinic. J. Pathol. 2012, 226 (2), 365–379. 
https://doi.org/10.1002/path.2993.Gene. 
(15)  Bennett, C. F. Therapeutic Antisense Oligonucleotides Are Coming of Age. Annu. Rev. 
ofMedicine 2019, 70 (1), 307–321. https://doi.org/10.1146/annurev-med-041217- 010829. 
(16)  Aartsma‐Rus, A.; Jackson, A. L.; Levin, A. A. Mechanisms of Oligonucleotide Actions. In 
Oligonucleotide ‐ Based Drugs and Therapeutics; Ferrari, N., Seguin, R., Eds.; John Wiley & 
Sons, Ltd, 2018; pp 1–37. 
(17)  Laina, A.; Gatsiou, A.; Georgiopoulos, G.; Stamatelopoulos, K. RNA Therapeutics in 
Cardiovascular Precision Medicine. 2018, 9, 953. https://doi.org/10.3389/fphys.2018.00953. 
eCollection 2018. 
(18)  Kitson, J. D. A.; Kamola, P. J.; Kane, L. Hybridization‐Dependent Effects: The Prediction, 
Evaluation,and Consequences of Unintended Target Hybridization. In Oligonucleotide ‐ Based 
Drugs and Therapeutics; Seguin, R., Ferrari, N., Eds.; John Wiley & Sons, Ltd, 2018; pp 191–
226. 
(19)  Macchi, C.; Sirtori, C. R.; Corsini, A.; Santos, R. D.; Watts, G. F. A New Dawn for Managing 
Dyslipidemias : The Era of Rna-Based Therapies. Pharmacol. Res. J. 2019, 150, 104413. 
https://doi.org/10.1016/j.phrs.2019.104413. 
(20)  Caillaud, M.; Madani, M. El; Massaad-massade, L. Small Interfering RNA from the Lab 
Discovery to Patients ’ Recovery. J. Control. Release 2020, 321, 616–628. 
https://doi.org/10.1016/j.jconrel.2020.02.032. 
(21)  Nikam, R. R.; Gore, K. R. Journey of SiRNA: Clinical Developments and Targeted Delivery. 
Nucleic Acid Ther. 2018, 28 (4), 209–224. https://doi.org/10.1089/nat.2017.0715. 
(22)  Niu, X.; Chen, J.; Gao, J. Nanocarriers as a Powerful Vehicle to Overcome Blood-Brain Barrier 




14 (5), 480–496. https://doi.org/10.1016/j.ajps.2018.09.005. 
(23)  Sweeney, M. D.; Zhao, Z.; Montagne, A.; Nelson, A. R.; Zlokovic, B. V. Blood-Brain Barrier: 
From Physiology to Disease and Back. Physiol. Rev. 2019, 99, 21–78. 
https://doi.org/10.1152/physrev.00050.2017. 
(24)  Hawkins, B. T.; Davis, T. P. The Blood-Brain Barrier / Neurovascular Unit in Health and 
Disease. Phamacological Rev. 2005, 57 (2), 173–185. https://doi.org/10.1124/pr.57.2.4.173. 
(25)  Pandit, R.; Chen, L.; Götz, J. The Blood-Brain Barrier: Physiology and Strategies for Drug 
Delivery. Adv. Drug Deliv. Rev. 2020, 165–166, 1–14. 
https://doi.org/10.1016/j.addr.2019.11.009. 
(26)  Weng, Y.; Huang, Q.; Li, C.; Yang, Y.; Wang, X.; Yu, J.; Huang, Y. Improved Nucleic Acid 
Therapy with Advanced Nanoscale Biotechnology. Mol. Ther. Nucleic Acid 2020, 19 (March), 
581–601. https://doi.org/10.1016/j.omtn.2019.12.004. 
(27)  Kuebler, A. R.; Pries, W. M. Normal Endothelium. In The Vascular Endothelium I. Handbook of 
Experimental Pharmacology; Moncada, S., Higgs, A., Eds.; Springer Berlin Heidelberg, 2006; pp 
1–40. 
(28)  Bellettato, C. M.; Scarpa, M. Possible Strategies to Cross the Blood – Brain Barrier. Ital. J. 
Pediatr. 2018, 44 (Suppl 2), 131. https://doi.org/10.1186/s13052-018-0563-0. 
(29)  Patel, M.; Patel, B. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the 
Brain. CNS Drugs 2017, 31 (2), 109–133. https://doi.org/10.1007/s40263-016-0405-9. 
(30)  Chen, Y.; Liu, L. Modern Methods for Delivery of Drugs across the Blood – Brain Barrier. Adv. 
Drug Deliv. Rev. 2012, 64 (7), 640–665. https://doi.org/10.1016/j.addr.2011.11.010. 
(31)  Ayloo, S.; Gu, C. Transcytosis at the Blood-Brain Barrier. Curr. Opin. Neurobiol. 2019, 57, 32–
38. https://doi.org/10.1016/j.conb.2018.12.014. 
(32)  Kimura, S.; Harashima, H. Current Status and Challenges Associated with CNS-Targeted Gene 
Delivery across the BBB. Pharmaceutics 2020, 12 (12), 1216. 
(33)  Patching, S. G. Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and 
Gateways for Drug Delivery. Mol. Neurobiol. 2017, 54, 1046–1077. 
https://doi.org/10.1007/s12035-015-9672-6. 
(34)  Li, H.; Qian, Z. M. Transferrin / Transferrin Receptor- Mediated Drug Delivery. Med. Res. Rev. 
2002, 22 (3), 225–250. https://doi.org/10.1002/med.10008. 
(35)  Preston, J. E.; Abbott, N. J.; Begley, D. J. Transcytosis of Macromolecules at the Blood – Brain 
Barrier. In Pharmacology of the Blood Brain Barrier: Targeting CNS Disorders; Davis, T., Ed.; 
Elsevier Inc., 2014; Vol. 71, pp 147–163. https://doi.org/10.1016/bs.apha.2014.06.001. 
(36)  Kiss, A. L.; Botos, E. Endocytosis via Caveolae : Alternative Pathway with Distinct Cellular 
Compartments to Avoid Lysosomal Degradation ? J. Cell. Mol. Med. 2009, 13 (7), 1228–1237. 
https://doi.org/10.1111/j.1582-4934.2009.00754.x. 
(37)  Schinkel, A. H.; Jonker, J. W. Mammalian Drug Efflux Transporters of the ATP Binding Cassette 
(ABC) Family : An Overview. Adv. Drug Deliv. Rev. 2003, 55, 3–29. 
(38)  Zhang, F.; Lin, Y.; Kannan, S.; Kannan, R. M.; Johns, T.; Medical, H. Targeting Specific Cells in 
the Brain with Nanomedicines For. J. Control. Release 20176, 240, 212–226. 
https://doi.org/10.1016/j.jconrel.2015.12.013. 
(39)  Setten, R. L.; Rossi, J. J.; Han, S.-P. The Current State and Future Directions of RNAi-Based 
Therapeutics. Nat. Rev. Drug Discov. 2019, 18 (6), 421–446. https://doi.org/10.1038/s41573-019-
0017-4. 
(40)  Yu, A. M.; Jian, C.; Yu, A. H.; Tu, M. J. RNA Therapy: Are We Using the Right Molecules? 
Pharmacol. Ther. 2019, 196, 91–104. https://doi.org/10.1016/j.pharmthera.2018.11.011. 
(41)  Geary, R. S.; Norris, D.; Yu, R.; Bennett, C. F. Pharmacokinetics, Biodistribution and Cell 
Uptake of Antisense Oligonucleotides. Adv. Drug Deliv. Rev. 2015, 87, 46–51. 
https://doi.org/10.1016/j.addr.2015.01.008. 
(42)  Deleavey, G. F.; Damha, M. J. Designing Chemically Modified Oligonucleotides for Targeted 
Gene Silencing. Chem. Biol. 2012, 19 (8), 937–954. 
https://doi.org/10.1016/j.chembiol.2012.07.011. 
(43)  Behlke, M. A. Chemical Modification of SiRNAs for in Vivo Use. Oligonucleotides 2008, 18 (4), 
305–319. https://doi.org/10.1089/oli.2008.0164. 
(44)  Papargyri, N.; Pontoppidan, M.; Andersen, M. R.; Koch, T.; Hagedorn, P. H. Chemical Diversity 
of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of 
Pharmaceutical Properties. Mol. Ther. - Nucleic Acids 2020, 19 (March), 706–717. 
https://doi.org/10.1016/j.omtn.2019.12.011. 
(45)  Min, H. S.; Kim, H. J.; Naito, M.; Ogura, S.; Toh, K.; Hayashi, K.; Kim, B. S.; Fukushima, S.; 




across the Blood–Brain Barrier with a Glucose‐Coated Polymeric Nanocarrier. Angew. Chemie 
2020, 132 (21), 8250–8257. https://doi.org/10.1002/ange.201914751. 
(46)  Alterman, J. F.; Godinho, B. M. D. C.; Hassler, M. R.; Ferguson, C. M.; Echeverria, D.; Sapp, E.; 
Haraszti, R. A.; Coles, A. H.; Conroy, F.; Miller, R.; Roux, L.; Yan, P.; Knox, E. G.; Turanov, A. 
A.; King, R. M.; Gernoux, G.; Mueller, C.; Gray-Edwards, H. L.; Moser, R. P.; Bishop, N. C.; 
Jaber, S. M.; Gounis, M. J.; Sena-Esteves, M.; Pai, A. A.; DiFiglia, M.; Aronin, N.; Khvorova, A. 
A Divalent SiRNA Chemical Scaffold for Potent and Sustained Modulation of Gene Expression 
throughout the Central Nervous System. Nat. Biotechnol. 2019, 37 (8), 884–894. 
https://doi.org/10.1038/s41587-019-0205-0. 
(47)  Schoch, K. M.; Miller, T. M. Antisense Oligonucleotides: Translation from Mouse Models to 
Human Neurodegenerative Diseases. Neuron 2017, 94 (6), 1056–1070. 
https://doi.org/10.1016/j.neuron.2017.04.010. 
(48)  Chi, X.; Gatti, P.; Papoian, T. Safety of Antisense Oligonucleotide and SiRNA-Based 
Therapeutics. Drug Discov. Today 2017, 22 (5), 823–833. 
https://doi.org/10.1016/j.drudis.2017.01.013. 
(49)  Selvam, C.; Mutisya, D.; Prakash, S.; Ranganna, K.; Thilagavathi, R. Therapeutic Potential of 
Chemically Modified SiRNA: Recent Trends. Chem. Biol. Drug Des. 2017, 90 (5), 665–678. 
https://doi.org/10.1111/cbdd.12993. 
(50)  Juliano, R. L. The Delivery of Therapeutic Oligonucleotides. Nucleic Acids Res. 2016, 44 (14), 
6518–6548. https://doi.org/10.1093/nar/gkw236. 
(51)  Amantana, A.; Iversen, P. L. Pharmacokinetics and Biodistribution of Phosphorodiamidate 
Morpholino Antisense Oligomers. Curr. Opin. Pharmacol. 2005, 5 (5), 550–555. 
https://doi.org/10.1016/j.coph.2005.07.001. 
(52)  Karaki, S.; Paris, C.; Rocchi, P. Antisense Oligonucleotides, A Novel Developing Targeting 
Therapy. In Antisense Therapy; IntechOpen, 2019. https://doi.org/10.5772/intechopen.82105. 
(53)  Rigo, F.; Chun, S. J.; Norris, D. A.; Hung, G.; Lee, S.; Matson, J.; Fey, R. A.; Gaus, H.; Hua, Y.; 
Grundy, J. S.; Krainer, A. R.; Henry, S. P.; Bennett, C. F. Pharmacology of a Central Nervous 
System Delivered 2′-O-Methoxyethyl- Modified Survival of Motor Neuron Splicing 
Oligonucleotide in Mice and Nonhuman Primates. J. Pharmacol. Exp. Ther. 2014, 350 (1), 46–
55. https://doi.org/10.1124/jpet.113.212407. 
(54)  Scoles, D. R.; Minikel, E. V.; Pulst, S. M. Antisense Oligonucleotides: A Primer. Neurol. Genet. 
2019, 5 (2), 1–8. https://doi.org/10.1212/NXG.0000000000000323. 
(55)  Rozners, E. RNA Metabolism and Drug Design. In Translational Medicine: Molecular 
Pharmacology and Drug Discovery; Meyers, R. A., Ed.; Wiley Online Library, 2018; pp 827–
869. 
(56)  Roberts, T. C.; Langer, R.; Wood, M. J. A. Advances in Oligonucleotide Drug Delivery. Nat. Rev. 
Drug Discov. 2020, 19, 673–694. https://doi.org/10.1038/s41573-020-0075-7. 
(57)  Wan, W. B.; Seth, P. P. The Medicinal Chemistry of Therapeutic Oligonucleotides. 2016. 
https://doi.org/10.1021/acs.jmedchem.6b00551. 
(58)  Peacock, H.; Kannan, A.; Beal, P. A.; Burrows, C. J. Chemical Modification of SiRNA Bases to 
Probe and Enhance RNA Interference. J. Org. Chem. 2011, 76 (18), 7295–7300. 
https://doi.org/10.1021/jo2012225. 
(59)  Yamakawa, K.; Nakano-Narusawa, Y.; Hashimoto, N.; Yokohira, M.; Matsuda, Y. Development 
and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment. Int. J. Mol. Sci. 
2019, 20 (17). https://doi.org/10.3390/ijms20174224. 
(60)  Sheng, L.; Rigo, F.; Bennett, C. F.; Krainer, A. R.; Hua, Y. Comparison of the Efficacy of MOE 
and PMO Modifications of Systemic Antisense Oligonucleotides in a Severe SMA Mouse Model. 
Nucleic Acids Res. 2020, 48 (6), 2853–2865. https://doi.org/10.1093/nar/gkaa126. 
(61)  Dirin, M.; Winkler, J. Influence of Diverse Chemical Modifications on the ADME Characteristics 
and Toxicology of Antisense Oligonucleotides. Expert Opin. Biol. Ther. 2013, 13 (6), 875–888. 
https://doi.org/10.1517/14712598.2013.774366. 
(62)  Shen, X.; Corey, D. R. Chemistry , Mechanism and Clinical Status of Antisense Oligonucleotides 
and Duplex RNAs. Nucleic Acids Res. 2019, 46 (4), 1584–1600. 
https://doi.org/10.1093/nar/gkx1239. 
(63)  Rodrigues, F. B.; Ferreira, J. J.; Wild, E. J. Huntington’s Disease Clinical Trials Corner: June 
2019. J. Huntingtons. Dis. 2019, 8 (3), 363–371. https://doi.org/10.3233/JHD-199003. 
(64)  Kazmi, F.; Sensenhauser, C.; Greway, T. Characterization of the in Vitro Inhibitory Potential of 
the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of in Vivo 





(65)  Singh, B. N.; Gupta, V. K.; Chen, J.; Atanasov, A. G. Organic Nanoparticle-Based Combinatory 
Approaches for Gene Therapy. Trends Biotechnol. 2017, 35 (12), 1121–1124. 
https://doi.org/10.1016/j.tibtech.2017.07.010. 
(66)  Costantino, L.; Boraschi, D. Is There a Clinical Future for Polymeric Nanoparticles as Brain-
Targeting Drug Delivery Agents ? Drug Discov. Today 2012, 17 (7–8), 367–378. 
https://doi.org/10.1016/j.drudis.2011.10.028. 
(67)  Yang, L.; Ma, F.; Liu, F.; Chen, J.; Zhao, X.; Xu, Q. Efficient Delivery of Antisense 
Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo. Mol. Ther. 
Nucleic Acid 2020, 19 (March), 1357–1367. https://doi.org/10.1016/j.omtn.2020.01.018. 
(68)  Riley II, M. K.; Vermerris, W. Recent Advances in Nanomaterials for Gene Delivery — A 
Review. Nanomaterials 2017, 1–19. https://doi.org/10.3390/nano7050094. 
(69)  Das, C. K.; Jena, B. C.; Banerjee, I.; Das, S.; Parekh, A.; Bhutia, S. K.; Mandal, M. Exosome as a 
Novel Shuttle for Delivery of Therapeutics across Biological Barriers. Mol. Pharm. 2019, 16, 24–
40. https://doi.org/10.1021/acs.molpharmaceut.8b00901. 
(70)  Zipkin, M. Exosome Redux. Nat. Biotechnol. 2019, 37, 1395–1400. 
https://doi.org/10.1038/s41587-019-0326-5. 
(71)  Seyfizadeh, N.; Seyfizadeh, N.; Borzouisileh, S.; Elahimanesh, F. Exosome-Mediated 
Therapeutic Delivery : A New Horizon for Human Neurodegenerative Disorders ’ Treatment ( 
with a Focus on SiRNA Delivery Improvement ). Process Biochem. 2019, 85, 164–174. 
https://doi.org/10.1016/j.procbio.2019.06.025. 
(72)  Yuan, Z.; Zhao, L.; Zhang, Y.; Li, S.; Pan, B.; Hua, L.; Wang, Z.; Ye, C. Inhibition of Glioma 
Growth by a GOLPH3 SiRNA-Loaded Cationic Liposomes. J. Neurooncol. 2018, 140 (2), 249–
260. https://doi.org/10.1007/s11060-018-2966-6. 
(73)  Conceição, M.; Mendonça, L.; Nóbrega, C.; Gomes, C.; Costa, P.; Hirai, H.; Moreira, J. N.; Lima, 
M. C.; Manjunath, N.; Pereira de Almeida, L. Intravenous Administration of Brain-Targeted 
Stable Nucleic Acid Lipid Particles Alleviates Machado-Joseph Disease Neurological Phenotype. 
Biomaterials 2016, 82, 124–137. https://doi.org/10.1016/j.biomaterials.2015.12.021. 
(74)  Chen, L.; Watson, C.; Morsch, M.; Cole, N. J.; Chung, R. S.; Saunders, D. N.; Yerbury, J. J.; 
Vine, K. L. Improving the Delivery of SOD1 Antisense Oligonucleotides to Motor Neurons 
Using Calcium Phosphate-Lipid Nanoparticle. Front. Neurosci. 2017, 11 (AUG), 1–12. 
https://doi.org/10.3389/fnins.2017.00476. 
(75)  Min, H. S.; Kim, H. J.; Naito, M.; Ogura, S.; Toh, K.; Hayashi, K.; Kim, B. S.; Fukushima, S.; 
Anraku, Y.; Miyata, K.; Kataoka, K. Systemic Brain Delivery of Antisense Oligonucleotides 
across the Blood–Brain Barrier with a Glucose-Coated Polymeric Nanocarrier. Angew. Chemie - 
Int. Ed. 2020, 0821, 8173–8180. https://doi.org/10.1002/anie.201914751. 
(76)  Karlsson, J.; Rui, Y.; Kozielski, K. L.; Placone, A. L.; Choi, O.; Tzeng, S. Y.; Kim, J.; Keyes, J. 
J.; Bogorad, M. I.; Gabrielson, K.; Guerrero-CAzares, H.; Quiñones-Hinojosa, A.; Searson, P. C.; 
Green, J. J. Engineered Nanoparticles for Systemic SiRNA Delivery to Malignant Brain 
Tumours. Nanoscale 2019, 11, 20045–20057. https://doi.org/10.1039/c9nr04795f. 
(77)  Ye, C.; Pan, B.; Xu, H.; Zhao, Z.; Shen, J.; Lu, J.; Yu, R. Co-Delivery of GOLPH3 SiRNA and 
Gefitinib by Cationic Lipid-PLGA Nanoparticles Improves EGFR-Targeted Therapy for Glioma. 
J. Mol. Med. 2019, 97, 1575–1588. https://doi.org/10.1007/s00109-019-01843-4. 
(78)  Heidel, J. D.; Yu, Z.; Liu, J. Y.; Rele, S. M.; Liang, Y.; Zeidan, R. K.; Kornbrust, D. J.; Davis, M. 
E. Administration in Non-Human Primates of Escalating Intravenous Doses of Targeted 
Nanoparticles Containing Ribonucleotide Reductase Subunit M2 SiRNA. PNAS 2007, 104 (14), 
5715–5721. https://doi.org/10.1073/pnas.0701458104. 
(79)  Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M. J. A. Delivery of SiRNA to 
the Mouse Brain by Systemic Injection of Targeted Exosomes. Nat. Biotechnol. 2011, 29 (4), 
341–347. https://doi.org/10.1038/nbt.1807. 
(80)  Kim, G.; Kim, M.; Lee, Y.; Woo, J.; Won, D.; Lee, M. Systemic Delivery of MicroRNA-21 
Antisense Oligonucleotides to the Brain Using T7-Peptide Decorated Exosomes. J. Control. 
Release 2020, 317, 273–281. https://doi.org/10.1016/j.jconrel.2019.11.009. 
(81)  Parashar, D.; Rajendran, V.; Shukla, R.; Sistla, R. Lipid-Based Nanocarriers for Delivery of 
Small Interfering RNA for Therapeutic Use. Eur. J. Pharm. Sci. 2020, 142 (August 2019), 
105159. https://doi.org/10.1016/j.ejps.2019.105159. 
(82)  Hoy, S. M. Patisiran : First Global Approval. Drugs 2018, 78 (15), 1625–1631. 
https://doi.org/10.1007/s40265-018-0983-6. 
(83)  Chung, Y. H.; Beiss, V.; Fiering, S. N.; Steinmetz, N. F. COVID-19 Vaccine Frontrunners and 
Their Nanotechnology Design. ACS Nano 2020. https://doi.org/10.1021/acsnano.0c07197. 




Therapeutics : Hallmarks of Non-Viral Gene Delivery. ACS Nano 2019, 13 (4), 3754–3782. 
https://doi.org/10.1021/acsnano.8b07858. 
(85)  Moss, K. H.; Popova, P.; Hadrup, S. R.; Astakhova, K.; Taskova, M. Lipid Nanoparticles for 
Delivery of Therapeutic RNA Oligonucleotides. Mol. Pharm. 2019, 16, 2265–2277. 
https://doi.org/10.1021/acs.molpharmaceut.8b01290. 
(86)  Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of Cationic Lipids and Cationic Polymers 
in Gene Delivery. J. Control. Release 2006, 114 (1), 100–109. 
https://doi.org/10.1016/j.jconrel.2006.04.014. 
(87)  Cullis, P. R.; Hope, M. J. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 
2017, 25 (7), 1467–1475. https://doi.org/10.1016/j.ymthe.2017.03.013. 
(88)  Rietwyk, S.; Peer, D. Next-Generation Lipids in RNA Interference Therapeutics. ACS Nano 
2017, 11 (8), 7572–7586. https://doi.org/10.1021/acsnano.7b04734. 
(89)  Cohen, Z. R.; Ramishetti, S.; Peshes-Yaloz, N.; Goldsmith, M.; Wohl, A.; Zibly, Z.; Peer, D. 
Localized RNAi Therapeutics of Chemoresistant Grade IV Glioma Using Hyaluronan-Grafted 
Lipid-Based Nanoparticles. ACS Nano 2015, 9 (2), 1581–1591. 
https://doi.org/10.1021/nn506248s. 
(90)  Rungta, R. L.; Choi, H. B.; Lin, P. J. C.; Ko, R. W. Y.; Ashby, D.; Nair, J.; Manoharan, M.; 
Cullis, P. R.; MacVicar, B. A. Lipid Nanoparticle Delivery of Sirna to Silence Neuronal Gene 
Expression in the Brain. Mol. Ther. - Nucleic Acids 2013, 2 (December), 1–12. 
https://doi.org/10.1038/mtna.2013.65. 
(91)  Cardoso, A. M.; Guedes, J. R.; Cardoso, A. L.; Morais, C.; Cunha, P.; Viegas, A. T.; Costa, R.; 
Jurado, A.; Pedroso de Lima, M. C. Recent Trends in Nanotechnology Toward CNS Diseases: 
Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery. Int. Rev. Neurobiol. 
2016, 130, 1–40. https://doi.org/10.1016/bs.irn.2016.05.002. 
(92)  Ashizawa, A. T.; Holt, J.; Faust, K.; Liu, W.; Tiwari, A.; Zhang, N.; Ashizawa, T. Intravenously 
Administered Novel Liposomes, DCL64, Deliver Oligonucleotides to Cerebellar Purkinje Cells. 
The Cerebellum 2019, 18 (1), 99–108. https://doi.org/10.1007/s12311-018-0961-2. 
(93)  Rai, R.; Alwani, S.; Badea, I. Polymeric Nanoparticles in Gene Therapy: New Avenues of Design 
and Optimization for Delivery Applications. Polymers (Basel). 2019, 11 (4). 
https://doi.org/10.3390/polym11040745. 
(94)  Xiang, Y.; Oo, N. N. L.; Lee, J. P.; Li, Z.; Loh, X. J. Recent Development of Synthetic Nonviral 
Systems for Sustained Gene Delivery. Drug Discov. Today 2017, 22 (9), 1318–1335. 
https://doi.org/10.1016/j.drudis.2017.04.001. 
(95)  Wang, Y.; Ye, M.; Xie, R.; Gong, S. Enhancing the in Vitro and in Vivo Stabilities of Polymeric 
Nucleic Acid Delivery Nanosystems. Bioconjug. Chem. 2019, 30 (2), 325–337. 
https://doi.org/10.1021/acs.bioconjchem.8b00749. 
(96)  Mc Carthy, D. J.; Malhotra, M.; O’Mahony, A. M.; Cryan, J. F.; O’Driscoll, C. M. Nanoparticles 
and the Blood-Brain Barrier: Advancing from in-Vitro Models towards Therapeutic Significance. 
Pharm. Res. 2015, 32 (4), 1161–1185. https://doi.org/10.1007/s11095-014-1545-6. 
(97)  Rafael, D.; Andrade, F.; Arranja, A.; Luís, S.; Videira, M. Lipoplexes and Polyplexes: Gene 
Therapy. Encycl. Biomed. Polym. Polym. Biomater. 2015, No. January, 4335–4347. 
https://doi.org/10.1081/e-ebpp-120050058. 
(98)  Lu, Y.; Jiang, C. Brain-Targeted Polymers for Gene Delivery in the Treatment of Brain Diseases. 
Top. Curr. Chem. 2017, 375 (2), 1–29. https://doi.org/10.1007/s41061-017-0138-3. 
(99)  Gomes, M. J.; Fernandes, C.; Martins, S.; Borges, F.; Sarmento, B. Tailoring Lipid and Polymeric 
Nanoparticles as SiRNA Carriers towards the Blood-Brain Barrier – from Targeting to Safe 
Administration. J. Neuroimmune Pharmacol. 2017, 12, 107–119. https://doi.org/10.1007/s11481-
016-9685-6. 
(100)  Mukherjee, A.; Waters, K.; Kalyan, P.; Achrol, A. S. Lipid – Polymer Hybrid Nanoparticles as a 
next- Generation Drug Delivery Platform : State of the Art , Emerging Technologies , and 
Perspectives. Int. J. Nanomedicine 2019, 14, 1937–1952. https://doi.org/10.2147/IJN.S198353. 
(101)  Jambhekar, S. S.; Breen, P. Cyclodextrins in Pharmaceutical Formulations I : Structure and 
Physicochemical Properties , Formation of Complexes , and Types of Complex. Drug Discov. 
Today 2016, 21 (2), 356–362. https://doi.org/10.1016/j.drudis.2015.11.017. 
(102)  Jacob, S.; Nair, A. B. Cyclodextrin Complexes : Perspective from Drug Delivery and 
Formulation. Drug Dev. Res. 2018, 79, 201–217. https://doi.org/10.1002/ddr.21452. 
(103)  Mellet, C. O. Cyclodextrin-Based Gene Delivery Systems. Chem. Soc. Rev. 2011, 40, 1586–1608. 
https://doi.org/10.1039/c0cs00019a. 
(104)  Coisne, C.; Tilloy, S.; Monflier, E.; Wils, D.; Fenart, L.; Gosselet, F. Cyclodextrins as Emerging 




Diseases. Molecules 2016, 21, 1748. https://doi.org/10.3390/molecules21121748. 
(105)  Zhang, J.; Ma, P. X. Cyclodextrin-Based Supramolecular Systems for Drug Delivery : Recent 
Progress and Future Perspective. Adv. Drug Deliv. Rev. 2013, 65 (9), 1215–1233. 
https://doi.org/10.1016/j.addr.2013.05.001. 
(106)  O’Mahony, A. M.; Godinho, B. M. D. C.; Cryan, J. F.; O’Driscoll, C. M. Non-Viral Nanosystems 
for Gene and Small Interfering RNA Delivery to the Central Nervous System : Formulating the 
Solution. J. Pharm. Biomed. Anal. 2013, 102, 3469–3484. https://doi.org/10.1002/jps.23672. 
(107)  Mohammed, A. F. A.; Motoyama, K.; Higashi, T.; Arima, H. Promising Use of Cyclodextrin-
Based Non-Viral Vectors for Gene and and Oligonucleotide Drugs. In Cyclodextrin - A Versatile 
Ingredient; Arora, P., Dhingra, N., Eds.; BoD – Books on Demand, 2018; pp 239–261. 
https://doi.org/10.5772/intechopen.74614. 
(108)  Godinho, B. M. D. C.; Ogier, J. R.; Darcy, R.; O’Driscoll, C. M.; Cryan, J. F. Self-Assembling 
Modi Fi Ed β ‑ Cyclodextrin Nanoparticles as Neuronal SiRNA Delivery Vectors: Focus on 
Huntington ’ s Disease. Mol. Pharm. 2013, 10 (2), 640–649. https://doi.org/10.1021/mp3003946. 
(109)  O’Mahony, A. M.; Godinho, B. M. D. C.; Ogier, J.; Devocelle, M.; Darcy, R.; Cryan, J. F.; 
O’Driscoll, C. M. Click-Modified Cyclodextrins as Nonviral Vectors for Neuronal SiRNA 
Delivery. ACS Chem. Neurosci. 2012, 3, 744–752. https://doi.org/dx.doi.org/10.1021/cn3000372. 
(110)  Gooding, M.; Malhotra, M.; Mccarthy, D. J.; Godinho, B. M. D. C.; Cryan, J. F.; Darcy, R.; 
O’Driscoll, C. M. Synthesis and Characterization of Rabies Virus Glycoprotein-Tagged 
Amphiphilic Cyclodextrins for SiRNA Delivery in Human Glioblastoma Cells : In Vitro 
Analysis. Eur. J. Pharm. Sci. 2015, 71, 80–92. 
(111)  Godinho, B. M. D. C.; Ogier, J. R.; Quinlan, A.; Darcy, R.; Grif, B. T.; Cryan, J. F.; O’Driscoll, 
C. M. PEGylated Cyclodextrins as Novel SiRNA Nanosystems : Correlations between 
Polyethylene Glycol Length and Nanoparticle Stability. Int. J. Pharm. 2014, 473, 105–112. 
https://doi.org/10.1016/j.ijpharm.2014.06.054. 
(112)  Hastings, C.; Vieira, C.; Liu, B.; Bascon, C.; Gao, C.; Wang, R. Y. Expanded Access with 
Intravenous Hydroxypropyl- β -Cyclodextrin to Treat Children and Young Adults with Niemann- 
Pick Disease Type C1 : A Case Report Analysis. Orphanet J. Rare Dis. 2019, 14, 228. 
https://doi.org/10.1186/s13023-019-1207-1. 
(113)  Osier, N.; Motamedi, V.; Edwards, K.; Puccio, A.; Diaz-Arrastia, R.; Kenney, K.; Gill, J. 
Exosomes in Acquired Neurological Disorders : New Insights into Pathophysiology and 
Treatment. Mol. Neurobiol. 2018, 55, 9280–9293. https://doi.org/10.1007/s12035-018-1054-4. 
(114)  Jiang, X.; Gao, J. Exosomes as Novel Bio-Carriers for Gene and Drug Delivery. Int. J. Pharm. 
2017, 521 (1–2), 167–175. https://doi.org/10.1016/j.ijpharm.2017.02.038. 
(115)  Gooding, M.; Malhotra, M.; Evans, J. C.; Darcy, R.; O’Driscoll, C. M. Oligonucleotide 
Conjugates – Candidates for Gene Silencing Therapeutics. Eur. J. Pharm. Biopharm. 2016, 107, 
321–340. https://doi.org/10.1016/j.ejpb.2016.07.024. 
(116)  Chernikov, I. V; Vlassov, V. V; Chernolovskaya, E. L. Current Development of SiRNA 
Bioconjugates : From Research to the Clinic. Front. Pharmacol. 2019, 10, 444. 
https://doi.org/10.3389/fphar.2019.00444. 
(117)  Zhang, R.; Qin, X.; Kong, F.; Chen, P.; Pan, G. Improving Cellular Uptake of Therapeutic 
Entities through Interaction with Components of Cell Membrane. Drug Deliv. 2019, 26 (1), 328–
342. https://doi.org/10.1080/10717544.2019.1582730. 
(118)  Mathupala, S. P. Delivery of Small-Interfering RNA (SiRNA) to the Brain. Expert Opin. Ther. 
Pat. 2010, 19 (2), 137–140. https://doi.org/10.1517/13543770802680195. 
(119)  Zhou, J.; Rossi, J. Aptamers as Targeted Therapeutics: Current Potential and Challenges. Nat. 
Rev. Drug Discov. 2017, 16, 181–202. https://doi.org/10.1038/nrd.2016.199. 
(120)  Catuogno, S.; Lucia, C.; Condorelli, G.; Franciscis, V. De. Nucleic Acids Delivering Nucleic 
Acids. Adv. Drug Deliv. Rev. 2018, 134, 79–93. https://doi.org/10.1016/j.addr.2018.04.006. 
(121)  Nuzzo, S.; Roscigno, G.; Alessandra, A.; Ingenito, F.; Quintavalle, C.; Condorelli, G. Potential 
and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision 
Medicine in Cancer. Cancers (Basel). 2019, 11, 1521. https://doi.org/10.3390/cancers11101521. 
(122)  Cheng, C.; Chen, Y. H.; Lennox, K. A.; Behlke, M. A.; Davidson, B. L. In Vivo SELEX for 
Identification of Brain-Penetrating Aptamers. Mol. Ther. - Nucleic Acids 2013, 2 (January), e67. 
https://doi.org/10.1038/mtna.2012.59. 
(123)  Macdonald, J.; Henri, J.; Goodman, L.; Xiang, D.; Duan, W.; Shigdar, S. Development of a 
Bifunctional Aptamer Targeting the Transferrin Receptor and Epithelial Cell Adhesion Molecule 
(EpCAM) for the Treatment of Brain Cancer Metastases. ACS Chem. Neurosci. 2017, 8 (4), 777–
784. https://doi.org/10.1021/acschemneuro.6b00369. 




Alder, J. E.; Ricci-vitiani, L.; Catuogno, S.; Franciscis, V. De. A Combined MicroRNA-Based 
Targeted Therapeutic Approach to Eradicate Glioblastoma Stem-like Cells. J. Control. Release 
2016, 238, 43–57. https://doi.org/10.1016/j.jconrel.2016.07.032. 
(125)  Esposito, C. L.; Nuzzo, S.; Catuogno, S.; Romano, S.; Nigris, F. De; Franciscis, V. De. STAT3 
Gene Silencing by Aptamer-SiRNA Chimera as Selective Therapeutic for Glioblastoma. Mol. 
Ther. Nucleic Acid 2018, 10 (March), 398–411. https://doi.org/10.1016/j.omtn.2017.12.021. 
(126)  Pardridge, W. M. Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan 
Horse Technology. BioDrugs 2017, 31 (6), 503–519. https://doi.org/10.1007/s40259-017-0248-z. 
(127)  Jones, A. R.; Shusta, E. V. Blood-Brain Barrier Transport of Therapeutics via Receptor-
Mediation. Pharm Res. 2007, 24 (9), 1759–1771. https://doi.org/10.1007/s11095-007-9379-
0.Blood-Brain. 
(128)  Johnsen, K. B.; Burkhart, A.; Thomsen, L. B.; Andresen, T. L.; Moos, T. Targeting the 
Transferrin Receptor for Brain Drug Delivery. Prog. Neurobiol. 2019, 181 (May), 101665. 
https://doi.org/10.1016/j.pneurobio.2019.101665. 
(129)  Xia, C. F.; Zhang, Y.; Zhang, Y.; Boado, R. J.; Pardridge, W. M. Intravenous SiRNA of Brain 
Cancer with Receptor Targeting and Avidin-Biotin Technology. Pharm. Res. 2007, 24 (12), 
2309–2316. https://doi.org/10.1007/s11095-007-9460-8. 
(130)  Arnold, A. E.; Malek-Adamian, E.; Le, P. U.; Meng, A.; Martínez-Montero, S.; Petrecca, K.; 
Damha, M. J.; Shoichet, M. S. Antibody-Antisense Oligonucleotide Conjugate Downregulates a 
Key Gene in Glioblastoma Stem Cells. Mol. Ther. - Nucleic Acids 2018, 11 (June), 518–527. 
https://doi.org/10.1016/j.omtn.2018.04.004. 
(131)  Xie, J.; Bi, Y.; Zhang, H.; Dong, S.; Teng, L.; Lee, R. J. Cell-Penetrating Peptides in Diagnosis 
and Treatment of Human Diseases : From Preclinical Research to Clinical Application. Front. 
Pharmacol. 2020, 11 (May), 1–23. https://doi.org/10.3389/fphar.2020.00697. 
(132)  Derakhshankhah, H.; Jafari, S. Biomedicine & Pharmacotherapy Cell Penetrating Peptides : A 
Concise Review with Emphasis on Biomedical Applications. Biomed. Pharmacother. 2018, 108 
(September), 1090–1096. https://doi.org/10.1016/j.biopha.2018.09.097. 
(133)  Benizri, S.; Gissot, A.; Martin, A.; Vialet, B. Bioconjugated Oligonucleotides: Recent 
Developments and Therapeutic Applications. Bioconjug. Chem. 2019, 30, 366–383. 
https://doi.org/10.1021/acs.bioconjchem.8b00761. 
(134)  Oller-Salvia, B.; Sánchez-Navarro, M.; Giralt, E.; Teixidó, M. Blood–Brain Barrier Shuttle 
Peptides: An Emerging Paradigm for Brain Delivery. Chem. Rev. 2016, 45, 4690–4707. 
https://doi.org/10.1039/c6cs00076b. 
(135)  Mcclorey, G.; Banerjee, S. Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-
Based Therapeutics. Biomedicines 2018, 1–15. https://doi.org/10.3390/biomedicines6020051. 
(136)  Kumar, P.; Wu, H.; Mcbride, J. L.; Jung, K.; Kim, M. H.; Davidson, B. L.; Kyung, S.; Shankar, 
P.; Manjunath, N. Transvascular Delivery of Small Interfering RNA to the Central Nervous 
System. Nature 2007, 448 (July), 39–45. https://doi.org/10.1038/nature05901. 
(137)  Wang, L.; Hao, Y.; Li, H.; Zhao, Y.; Meng, D.; Li, D.; Shi, J.; Zhang, H. Co-Delivery of 
Doxorubicin and SiRNA for Glioma Therapy by a Brain Targeting System : Angiopep-2-
Modified Poly ( Lactic-Co-Glycolic Acid ) Nanoparticles. J. Drug Target. 2015, 2330, 1–15. 
https://doi.org/10.3109/1061186X.2015.1025077. 
(138)  Osborn, M. F.; Khvorova, A. Improving SiRNA Delivery In Vivo Through Lipid Conjugation. 
Nucleic Acid Ther. 2018, 28 (3), 128–136. https://doi.org/10.1089/nat.2018.0725. 
(139)  Biscans, A.; Coles, A.; Echeverria, D.; Khvorova, A. The Valency of Fatty Acid Conjugates 
Impacts SiRNA Pharmacokinetics, Distribution, and Efficacy in Vivo. J. Colloid Interface Sci. 
2019, 302, 116–125. https://doi.org/10.1016/j.jconrel.2019.03.028.The. 
(140)  Biscans, A.; Coles, A.; Haraszti, R.; Echeverria, D.; Hassler, M.; Osborn, M.; Khvorova, A. 
Diverse Lipid Conjugates for Functional Extra-Hepatic SiRNA Delivery in Vivo. Nucleic Acids 
Res. 2019, 47 (3), 1082–1096. https://doi.org/10.1093/nar/gky1239. 
(141)  Godinho, B. M. D. C.; Gilbert, J. W.; Haraszti, R. A.; Coles, A. H.; Biscans, A.; Roux, L.; Nikan, 
M.; Echeverria, D.; Hassler, M.; Khvorova, A. Pharmacokinetic Profiling of Conjugated 
Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood 
Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay. Nucleic Acid Ther. 2017, 
27 (6), 323–334. https://doi.org/10.1089/nat.2017.0690. 
(142)  Nikan, M.; Osborn, M. F.; Coles, A. H.; Godinho, B. M. D. C.; Hall, L. M.; Haraszti, R. A.; 
Hassler, M. R.; Echeverria, D.; Aronin, N.; Khvorova, A. Docosahexaenoic Acid Conjugation 
Enhances Distribution and Safety of SiRNA upon Local Administration in Mouse Brain. Mol. 
Ther. - Nucleic Acids 2016, 5, e344. https://doi.org/10.1038/mtna.2016.50. 




Sapp, E.; Echeverria, D.; Aronin, N.; Khvorova, A. Synthesis and Evaluation of Parenchymal 
Retention and Efficacy of a Metabolically Stable, O-Phosphocholine-N- Docosahexaenoyl-L-
Serine SiRNA Conjugate in Mouse Brain. Bioconjug. Chem. 2017, 28 (6), 1758–1766. 
https://doi.org/10.1021/acs.bioconjchem.7b00226.Synthesis. 
(144)  Chen, D.; Ganesh, S.; Wang, W.; Amiji, M. Protein Corona-Enabled Systemic Delivery and 
Targeting of Nanoparticles. AAPS J. 2020, 22, 83. https://doi.org/10.1208/s12248-020-00464-x. 
(145)  Zhang, Z.; Guan, J.; Jiang, Z.; Yang, Y.; Liu, J.; Hua, W.; Mao, Y.; Li, C.; Lu, W.; Qian, J.; Zhan, 
C. Brain-Targeted Drug Delivery by Manipulating Protein Corona Functions. Nat. Commun. 
2019, 10, 3561. https://doi.org/10.1038/s41467-019-11593-z. 
(146)  Dal Magro, R.; Albertini, B.; Beretta, S.; Rigolio, R.; Donzelli, E.; Chiorazzi, A.; Ricci, M.; 
Blasi, P.; Sancini, G. Artificial Apolipoprotein Corona Enables Nanoparticle Brain Targeting. 
Nanomedicine Nanotechnology, Biol. Med. 2018, 14 (2), 429–438. 
https://doi.org/10.1016/j.nano.2017.11.008. 
(147)  Wang, H.; Eckel, R. H. What Are Lipoproteins Doing in the Brain ? Trends Endocrinol. Metab. 
2014, 25 (1), 8–14. https://doi.org/10.1016/j.tem.2013.10.003. 
(148)  Zuckerman, J. E.; Davis, M. E. Clinical Experiences with Systemically Therapeutics in Cancer. 
Nat. Rev. Drug Discov. 2015, 14, 843–856. https://doi.org/10.1038/nrd4685. 
(149)  Subhan, A.; Torchilin, V. P. SiRNA Based Drug Design, Quality, Delivery and Clinical 
Translation. Nanomedicine Nanotechnology, Biol. Med. 2020, 29, 102239. 
https://doi.org/10.1016/j.nano.2020.102239. 
(150)  Davidson, B. L. Doubling down on SiRNAs in the Brain. Nat. Biotechnol. 2019, 37, 865–868. 
https://doi.org/10.1038/s41587-019-0204-1. 
(151)  Di Napoli, R.; Esposito, G.; Cascella, M. Intrathecal Catheter. In Treasure Island (FL): 
StatPearls [Internet]; StatPearls Publishing, 2020. 
(152)  Rinaldi, C.; Wood, M. J. A. Antisense Oligonucleotides: The next Frontier for Treatment of 
Neurological Disorders. Nat. Rev. Neurol. 2018, 14 (1), 9–22. 
https://doi.org/10.1038/nrneurol.2017.148. 
(153)  Weng, Y.; Huang, Y. The Advances of Biomacromolecule-Based Nanomedicine in Brain 
Disease. In Nanomedicine in Brain Diseases; Xue, X., Ed.; Springer Singapore, 2019; pp 181–
208. https://doi.org/https://doi.org/10.1007/978-981-13-8731-9_7. 
(154)  Conniot, J.; Talebrian, S.; Simões, S.; Ferreira, L.; Conde, J. Revisiting Gene Delivery to the 
Brain: Silencing and Editing. Biomater. Sci. 2020. https://doi.org/10.1039/D0BM01278E. 
(155)  Liu, X. S.; Jaenisch, R. Editing the Epigenome to Tackle Brain Disorders Trends in 
Neurosciences. Trends Neurosci. 2019, 42 (12), 861–870. 
https://doi.org/10.1016/j.tins.2019.10.003. 
(156)  Khan, S. H. Genome-Editing Technologies : Concept , Pros , and Cons of Various Genome-
Editing Techniques and Bioethical Concerns for Clinical Application. Mol. Ther. Nucleic Acid 
2019, 16 (June), 326–334. https://doi.org/10.1016/j.omtn.2019.02.027. 
 
 
 
 
